Statistical Issues in the Design and Analysis of Sequentially Randomized Trials by Ko, Jin Hui
STATISTICAL ISSUES IN THE DESIGN AND
ANALYSIS OF SEQUENTIALLY RANDOMIZED
TRIALS
by
Jin Hui Ko
B.S., Myongji University, South Korea, 2000
M.E., Texas A&M University, 2003
Submitted to the Graduate Faculty of
the Department of Biostatistics in partial fulllment
of the requirements for the degree of
Doctor of Philosophy
University of Pittsburgh
2010
UNIVERSITY OF PITTSBURGH
GRADUATE SCHOOL OF PUBLIC HEALTH
This dissertation was presented
by
Jin Hui Ko
It was defended on
July 26, 2010
and approved by
Dissertation Advisor:
Abdus S. Wahed, PhD
Associate Professor
Department of Biostatistics
Graduate School of Public Health
University of Pittsburgh
Committee Member:
Stewart Anderson, PhD
Professor
Department of Biostatistics
Graduate School of Public Health
University of Pittsburgh
Committee Member:
Jong-Hyeon Jeong, PhD
Associate Professor
Department of Biostatistics
Graduate School of Public Health
University of Pittsburgh
Committee Member:
Yu Cheng, PhD
Assistant Professor
Department of Statistics
School of Arts and Sciences
University of Pittsburgh
ii
STATISTICAL ISSUES IN THE DESIGN AND ANALYSIS OF
SEQUENTIALLY RANDOMIZED TRIALS
Jin Hui Ko, PhD
University of Pittsburgh, 2010
Adaptive treatment strategies are comprehensive methods for treating chronic diseases ac-
cording to patients' needs and responses. They are useful in the treatment of diseases such as
cancer or AIDS, where the treatment is frequently modied to adapt to the patients' health
status. In the rst part of this dissertation, we consider two commonly used randomization
designs in clinical trial, namely, up-front randomized trial and sequentially randomized trial
used to compare treatment strategies. Up-front randomization is the classical method of
randomization where patients are randomized at the beginning of the study to pre-specied
strategies. On the other hand, in sequentially randomization trials, patients are randomized
sequentially to available treatment options over the duration of the therapy as they become
eligible to receive them. We compare the eciency of the traditional up-front randomized
trials to that of sequentially randomized trials for comparing adaptive treatment strategies
both analytically and numerically based on a continuous outcome.
In the second part of the dissertation, we consider analyzing right-censored survival
data from two-stage sequentially randomized trials. In such analysis, it is often of interest to
use median residual lifetime as the summary parameter to assess the treatment eectiveness.
However, estimation of the median residual lifetime from sequentially randomized trials is not
as straightforward because of its sequential randomization structure. We propose methods
for estimating strategy-specic median residual life function from a two-stage sequentially
randomized trial. Two types of estimators are proposed by inverting the inverse-probability-
weighted estimated survival function and by using inverse-probability-weighted estimating
iii
equation function. We provide methods for estimating variances of these estimators and
compare them through a simulation study. Our simulation study shows that both methods
produce approximately unbiased estimators in large samples. We demonstrate our methods
by applying them to a sequentially randomized leukemia clinical trial data set.
Diseases such as cancer, leukemia, depression, and AIDS are major causes of morbidity
and mortality in the United States. Medical research in the recent times has focused on nd-
ing optimal treatment strategies to manage or eradicate these diseases to reduce individual
and community burdens. Statistical methodologies proposed in this dissertation will help
appropriately design and analyze trials to develop eective treatment strategies and thus
will be of signicant use for improving public health in the United States and around the
world.
Keywords: Adaptive Treatment Strategies, Dynamic Treatment Regime, Inverse Proba-
bility Weighting, Sequential Randomization, Two-Stage Randomization Design, Median
Residual Life Function.
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1.0 INTRODUCTION
1.1 ADAPTIVE TREATMENT STRATEGY (ATS)
Adaptive treatment strategies are comprehensive methods for treating chronic diseases ac-
cording to patients' needs and responses. They are useful in the treatment of diseases such
as cancer or AIDS, where the treatment is frequently modied to adapt to the patients'
health status. For example, in the treatment of acute myeloid leukemia, it is of interest to
know whether growth factor infusion should be used following induction chemotherapy, or
whether a mono-therapy or a combination therapy should be used as maintenance following
remission. Usually, these questions are addressed locally by comparing the treatments at
specic stages of the disease. However, a locally optimum treatment (e.g. the best induc-
tion for archiving remission) may not be the best globally (e.g. extended overall survival).
Therefore, instead of considering each treatment separately, ATSs are formed to consider all
treatment options at once for the purpose of the analysis. For example, in the treatment of
leukemia, one ATS might be \treat with induction chemotherapy and add a growth factor;
if remission is achieved, treat with a combination maintenance therapy; if remission is not
achieved, declare that patient to be a treatment failure". Another such strategy can just
avoid the growth factor. Treatment options at each evaluation time determine the possible
ATSs.
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1.2 RANDOMIZATIONS IN CLINICAL TRIALS
Up-front randomized trial (URT) and sequentially randomized trial (SRT) are two methods
to randomize patients to dierent strategies in order to compare treatment strategies. Up-
front randomization is the classical method of randomization which randomizes patients at
the beginning of the study to pre-specied strategies. Sequential randomization randomizes
patients sequentially to possible treatments as they become eligible to receive subsequent
treatment. An illustration of URT and SRT with two stages of treatment is presented in
Figure 1.
Suppose Ai denotes the i
th induction treatment, Bk is the k
th maintenance treatment for
the responders and Cl is the l
th alternative treatment for the non-responders. For simplicity,
we assume that there are two varieties of A, B and C, and thus j, k and l can take values
1 and 2. In practice, the alternative treatment C can be one of the induction treatments
that were not received by the patients at stage 1 (see Thall et al. [2007]). In some terminal
illnesses, such as leukemia in elder patients, if a response (remission) is not achieved with
an induction, no further treatment is given to reduce the treatment-related mortality and
therefore C can be regarded as no treatment. In this case, patients without response to the
induction treatment do not receive any further treatment.
As can be seen from Figure 1(a), in URT, patients are randomized upon entry to all
possible treatment strategies (a total of 8, in this case), realizing that some of the patients
will not receive the intended maintenance or alternative treatment. For example, patient
randomized to A1B1C1 will receive B1 only if they respond to A1 and C1 only if they do not
respond to A1. Thus, even if randomized with equal probability, for example, to A1B1C1 and
A1B1C2, the actual number of patients receiving C1 and C2 can be very dierent depending
on the number of patients not responding to A1 in the two arms. URT is simple to conduct
and the traditional method of analysis can be easily applied to analyze the data from such
trials. Statistical analysis for comparing strategies follows standard method of multiple
treatment trials.
In SRT (Figure 1(b)), patients are randomized to one of the two rst-stage treatments
A1 or A2 at entry. Once a patient achieves response, he/she is randomized to the second-
2
stage treatments B1 or B2 and to C1 or C2 if not. As can be seen, patients responding
to the induction treatment can be randomized to two maintenance treatments B1 or B2
by maintaining balance if desired. Similarly, if desired a balance in the number of patients
between two alternative treatments C1 and C2 can be attained. SRTs are often referred to as
SMART (Sequential Multiple Assignment Randomized Trials, Murphy [2005]). Even though
more complex statistical methods are required to compare treatment strategies, SRT follows
the traditional principle of randomizing patients at the time of ascertaining eligibility.
1.3 MEDIAN RESIDUAL LIFE FUNCTION
A MERL function is the median of the remaining life time at a specic time point. For
overall survival T , median residual lifetime at time t0 is dened as:
(t0) = median(T   t0jT  t0);
where median(XjY ) stands for the median of the conditional distribution of X given con-
dition Y . In other words, (t0) is the median time for those who survived beyond time t0
in the population. The median residual lifetime is stable since it is not aected by outliers
such as very long durations of survival time. In the case with the censored data, the use of
a median for the residual lifetime not only exhibits a better location estimate than its mean
but also shows less sensitivity to skewed distributions. The minimum of observed survival
probability of the residual life distribution should be smaller than the 0:5, so that the median
residual lifetime can be dened under censoring (Schmittlein et al. [1981]).
Various methods have been proposed in the literature to estimate the median residual
lifetimes for one and two sample cases. Haines et al. [1974] introduced a general concept of
the -percentile residual life function (0 <  < 1). Schmittlein et al. [1981] established a
general concept of MERL function exploring non-uniqueness of the corresponding lifetime
distribution. Csorgo et al. [1987] proposed a 100(1   p)th percentile residual lifetime esti-
mator for complete data, whereas Chung [1989] extended this idea to censoring cases. The
nonparametric estimator of 100(1   p)th percentile residual lifetime was proposed by Feng
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(a) Up-front randomized trial
(b) Sequentially randomized trial
Figure 1: Illustrations of (a) URT and (b) SRT with two stages of treatment
et al. [1991], where inverse function of the Kaplan-Meier curve was used. Jeong et al. [2008]
introduced a test statistic to compare two median residual lifetimes at a certain time point.
4
1.4 OBJECTIVE
The primary objective of this dissertation is two-fold : (a) compare the eciency of the
traditional up-front randomized trials to that of sequentially randomized trials for compar-
ing adaptive treatment strategies and (b) propose methods for estimating strategy-specic
median residual life function. We use the probability-adjusted survival estimator to estimate
median residual life function.
To achieve the rst goal, we construct unbiased estimators under both URT and SRT,
and compared their analytical and estimated variances. We present the results in Chapter 3.
We then propose two forms of estimators for the median residual lifetime from sequentially
randomized trials. These are obtained by inverting the estimated survival function and using
the estimating functions. The results are presented in Chapter 4.
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2.0 METHODOLOGY REVIEWS
In the following, we review some of techniques used in this dissertation.
2.1 KAPLAN-MEIER ESTIMATOR
The Kaplan-Meier Estimator is a nonparametric method used to estimate a survival curve
from lifetime data. Life time data is usually right censored and hence the empirical distribu-
tion function does not directly apply to the estimation of the survival distribution. Let S(t)
be the survival probability exceeding a time t. The Kaplan-Meier estimator is formulated as
follows from the sample data containing N observed times (event/censoring times).
S^(t) = ti<t
ni   di
ni
; i = 1 : : : N;
where ti's are event times, ni is the number of survivors excluding censored cases at time ti
and di is the number of events occurred at time ti. The variance of this estimator is generally
approximated using the Greenwood formula:
var(S^(t)) = S^2(t)
X
ti<t
di
ni(ni   di) :
The Kaplan-Meier estimator is known to be unbiased in large samples and is asymptoti-
cally normally distributed with mean S(t) and variance that can be estimated by the above
formula.
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2.2 INVERSE-PROBABILITY-WEIGHTED ESTIMATOR
The idea of inverse-probability-weighting originates from the survey sampling where the
inverse of the probability of sampling an individual unit is used as weight for that unit
to construct unbiased estimators (Horvitz et al. [1952]). The idea can be extended to the
estimation of survival curve in the presence of censoring. When censoring is considered
independent of the observed data, the complete observation can be viewed as independent
sample of the whole data. Thus, only the complete observations can be used to empirically
estimate the survival functions with individual probability of not being censored as the
reciprocal of weights.
Let Ui = min(Ti; Ci) be the observed survival time, i = I(Ti < Ci) be the event
indicator where Ti is the event time and Ci is the potential censoring time for the i
th patient
that for a xed time t. The inverse probability of censoring weighted estimator of S(t) is
given by
S^IPW (t) = n
 1
nX
i=1
i
K^(Ui)
I(Ui > t)
where K^(Ui) is the Kaplan-Meier estimator for censoring.
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3.0 UP-FRONT VS. SEQUENTIAL RANDOMIZATION IN CLINICAL
TRIALS
3.1 INTRODUCTION
Recently, SRTs have drawn considerable attention as an eective way of comparing ATSs.
Analytical methods for comparing treatment strategies from SRTs are available in the lit-
erature (Lunceford et al. [2002], Murphy [2005], Robins et al. [1994], Wahed and Tsiatis
[2004]). However, there is no literature on how SRT compares to URT in terms of statistical
inference - particularly with respect to the eciency of the estimators and the power of
statistical hypothesis testing. In Wolbers et al. [2008], by using an estimator from Lunceford
et al. [2002], several URTs were compared with a single SRT to show how new induction and
maintenance treatments are benecial over the existing treatment combinations. In their
work, authors show that SRT is better than URT with respect to ecient use of information
about patients. However, comparison does not include the eciency of estimators.
In this chapter, we derive estimators of the mean of a continuous outcome for URT
and SRT with two-stage designs by using the inverse-probability-weighting (IPW) (Robins
et al. [1994]). Then we aim to evaluate the performance of the estimators for URT and SRT
in terms of the eciency of the estimators and the power of statistical hypothesis testing.
Assumptions and notation used in this chapter are described in section 3.2. Inferential pro-
cedures in URT and SRT are discussed in section 3.3. We present the results of a simulation
study in section 3.4.
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3.2 NOTATION AND ASSUMPTIONS
Suppose there are two induction treatments Aj, j = 1; 2, two maintenance treatments for
responders Bk, k = 1; 2, and two alternative treatments for non responders Cl, l = 1; 2.
Let us dene Y to be the outcome variable of interest. We will treat Y as being con-
tinuous; however, the methodology can be applied analogously to binary responses. We will
dene the estimands in terms of patient-specic counterfactual variables (Holland [1986]).
Let Yi(AjBk) denote the outcome of the individual i if he/she actually received the treat-
ment sequence AjBk (Receive Aj, respond, and then receive Bk). Similarly, let Yi(AjCl) be
the outcome of the same patient if he/she had received the sequence AjCl. Note that under
the possible options for induction and maintenance, there are 8 such outcomes possible. In
practice, only one of the sequences will be followed by one individual. Therefore, only one
of these 8 outcomes will be observed If Ri denotes the response status (Ri = 1 for response,
0 for no response) for the patient i in the population, then the outcome Y for the patients i
under strategy AjBkCl can be written as
Yi(AjBkCl) = RiYi(AjBk) + (1 Ri)Yi(AjCl); j; k; l = 1; 2: (3.1)
To represent a generic individual, for simplicity, we will drop i from the variable notation,
wherever possible.
Our goal is to estimate
jkl = EfY (AjBkCl)g:
Note that conditioning on R, jkl can be expressed as
jkl = RjAjBk + (1  Rj)AjCl ;
where AjBk = EfY (AjBk)g, AjCl = EfY (AjCl)g and Rj is the probability of response to
induction treatment Aj. All the variables Y (AjBk); Y (AjCl) and Y (AjBkCl); j; k; l = 1; 2
are counterfactuals, as they all cannot be observed for the same individual. Regardless of
the design of the study, that is, whether URT or SRT, the observed data can be written as
fIi(Aj); Ri; RiIi(Bk); (1   Ri)Ii(Cl); Yi; j; k; l = 1; 2g; i = 1; 2; :::; n, where Yi is the observed
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outcome for the ith patient, Ii(X) is the indicator function for treatment X. Ii(X) = 1 if
the ith patient was assigned to receive treatment X, and 0, otherwise.
3.3 ESTIMATION IN UP-FRONT AND SEQUENTIALLY RANDOMIZED
TRIALS
In this section, we construct unbiased estimators for jkl under the two randomized designs,
URT and SRT, and derive their variances in order to compare their eciency.
3.3.1 Estimation in Up-front Randomized Trials
In URT, patients are randomized at the beginning into 8 eligible strategies. Therefore, the
estimator for the mean outcome jkl in URT is given by the sample mean of the outcome
for patients randomized to the strategy AjBkCl. Specically,
^URTjkl =
Pn
i=1 YiIi(AjBkCl)Pn
i=1 Ii(AjBkCl)
=
Pn
i=1 YiIi(AjBkCl)
njkl
;
where Ii(AjBkCl) = Ii(Aj)fRiIi(Bk) + (1   Ri)Ii(Cl)g and njkl =
Pn
i=1 Ii(AjBkCl). The
variance of this estimator is given by
Var(^URTjkl ) =
VarfY (AjBkCl)g
njkl
:
Now, by the law of conditioned variance,
VarfY (AjBkCl)g = Var

EfY (AjBkCl)jRg

+ E

VarfY (AjBkCl)jRg

: (3.2)
First, consider the rst part of the right-hand side in Eq. (3.2). Using Eq. (3.1),
EfY (AjBkCl)jRg =REfY (AjBk)jRg+ (1 R)EfY (AjCl)jRg
=RAjBk + (1 R)AjCl :
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Note that E[EfY (AjBkCl)jRg] = AjBk + (1  )AjCl . Then, its variance would be
Var

EfY (AjBkCl)jRg

=E

EfY (AjBkCl)jRg2
  fAjBk + (1  )AjClg2
=E
fRE(Y (AjBk)jR) + (1 R)E(Y (AjCl)jR)g2
  fAjBk + (1  )AjClg2
=EfR2AjBk + (1 R)2AjClg   fAjBk + (1  )AjClg2
=2AjBk + (1  )2AjCl   fAjBk + (1  )AjClg2: (3.3)
Similarly for the second term,
VarfY (AjBkCl)jRg =VarfRY (AjBk) + (1 R)Y (AjCl)jRg
=Ef(RY (AjBk) + (1 R)Y (AjCl))2jRg
  [REfY (AjBk)jRg+ (1 R)EfY (AjCl)jRg]2
=REfY (AjBk)2jRg+ (1 R)EfY (AjCl)2jRg
 R[EfY (AjBk)g]2   (1 R)[EfY (AjCl)g]2:
=R(2AjBk + 
2
AjBk
) + (1 R)(2AjCl + 2AjCl)
 R2AjBk   (1 R)2AjCl ;
whose expected value is given by
E

VarfY (AjBkCl)jRg

=(2AjBk + 
2
AjBk
) + (1  )(2AjCl + 2AjCl)
  2AjBk   (1  )2AjCl : (3.4)
Then, by combining Eq. (3.3) and Eq. (3.4), the variance of ^URTjkl is
Var(^URTjkl ) =
1
njkl

(2AjBk + 
2
AjBk
) + (1  )(2AjCl + 2AjCl)
   AjBk + (1  )AjCl2: (3.5)
When randomization is done with equal probability to 8 dierent strategies, then njkl  n=8
and the variance in Eq. (3.5) can be written as
8
n
n
(2AjBk + 
2
AjBk
) + (1  )(2AjCl + 2AjCl) 
 
AjBk + (1  )AjCl
2o
: (3.6)
The variance of the estimator ^URTjkl can be estimated by the sample variance for individual
groups.
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3.3.2 Estimation with Inverse-probability-weighting in Sequentially Random-
ized Trials
SRT randomizes patients rst into one of the two A treatments (A1; A2), then depending on
the response, further randomizes to B or C treatments. Responders are randomized to B1
or B2 while non-responders to C1 or C2. Consider only patients who received Aj (j=1 or
2). Using the idea of inverse-probability-weighting (IPW) (Robins et al. [1994]), an unbiased
estimator for jkl can be expressed as the average of the weighted outcome of responders
and non-responders as follows
^SRTjkl =
1
nj
njX
i=1

RiIi(Bk)
Pk
+
(1 Ri)Ii(Cl)
Ql

Yi; (3.7)
where Pk and Ql are the probability of the responders receiving Bk and non-responders
receiving Cl, respectively, and nj is the number of patients assigned to Aj at the entry,
i.e., nj =
Pn
i=1 Ii(Aj). The fact that ^
SRT
jkl is unbiased can be shown by using the consis-
tency assumption (Cole [2009]). In terms of the counterfactuals and the observed data, the
consistency assumption can be written as
Yi =
nX
i=1
Ii(Aj)
(
Ri
nX
k=1
Ii(Bk)Yi(AjBk) + (1 Ri)
nX
l=1
Ii(Cl)Yi(AjCl)
)
: (3.8)
The consistency assumption states that a patient's counterfactual outcome under a given
strategy equals the observed outcome under treatment assignment consistent to the same
strategy. Now, under Eq. (3.8), Eq. (3.7) can be written as
^SRTjkl =
1
nj
njX
i=1

RiIi(Bk)
Pk
Yi(AjBk) +
(1 Ri)Ii(Cl)
Ql
Yi(AjCl)

:
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Unbiasedness of this estimator can be shown by using the sequential randomization assump-
tion as follows
E[^SRTjkl ] =
1
nj
njX
i=1
E

RiIi(Bk)
Pk
Yi(AjBk) +
(1 Ri)Ii(Cl)
Ql
Yi(AjCl)

=
1
nj
njX
i=1

1
Pk
E fRiYi(AjBk)E[I(Bk)jRi; Yi(AjBk)]g
+
1
Ql
E f(1 Ri)Yi(AjCl)E[I(Cl)jRi; Yi(AjCl)]g

=
1
nj
njX
i=1
1
Pk
E [RiYi(AjBk)Pk] +
1
Ql
E [(1 Ri)Yi(AjCl)Ql]
=
1
nj
njX
i=1
E[RiYi(AjBk) + (1 Ri)Yi(AjCl)]
=
1
nj
njX
i=1
E[Yi(AjBkCl)]
=jkl;
where the sequential randomization assumption was used from going to the third line from
the second, which states that the probability of receiving a treatment given the history of
the observed data does not depend on counterfactuals. In the case of receiving treatment
Bk, this assumption can be written as Ii(Bk) ? fYi(AjBk); Yi(AjCl)gjRi.
The variance of ^SRTjkl is obtained in a similar manner as Var(^
URT
jkl ). Let ^
SRT
jkl =
(1=nj)
Pnj
i=1Hi where Hi = [fYi(AjBk)RiIi(Bk)g=Pk + fYi(AjCl)(1   Ri)Ii(Cl)g=Ql]. Then
the variance of ^SRTjkl can be expressed as
Var(^SRTjkl ) =
Var(H)
nj
;
where H =
Pn
i=1Hi.
Now,
Var(H) = E [VarfHjR; Y (AjBk); Y (AjCl)g] + Var [EfHjR; Y (AjBk); Y (AjCl)g] : (3.9)
Starting with the conditional variance,
Var(HjR; Y (AjBk); Y (AjCl)) =R(Y (AjBk))2 (1  Pk)
Pk
+ (1 R)(Y (AjCl))2 (1 Ql)
Ql
:
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The expected value of the conditional variance
EfVar(HjR; Y (AjBk); Y (AjCl)g
=E

R(Y (AjBk)
2 (1  Pk)
Pk
+ (1 R)(Y (AjCl))2 (1 Ql)
Ql

=E

E

RfY (AjBk)g2 (1  Pk)
Pk
+ (1 R)fY (AjCl)g2 (1 Ql)
Ql
jR

=E

R(2AjBk + 
2
AjBk
)
(1  Pk)
Pk
+ (1 R)(2AjCl + 2AjCl)
(1 Ql)
Ql

=(2AjBk + 
2
AjBk
)
(1  Pk)
Pk
+ (1  )(2AjCl + 2AjCl)
(1 Ql)
Ql
: (3.10)
For the second part of the right hand side in Eq. (3.9),
E(HjR; Y (AjBk); Y (AjCl)) =

R
Pk
Y (AjBk)EfI(Bk)jR; Y (AjBk)g
+
(1 R)
Ql
Y (AjCl)EfI(Cl)jR; Y (AjCl)g

=RY (AjBk) + (1 R)Y (AjCl)
=Y (AjBkCl);
the variance of which is
Var[EfHjR; Y (AjBk); Y (AjCl)g] = (2AjBk + 2AjBk) + (1  )(2AjCl + 2AjCl)
   AjBk + (1  )AjCl2 : (3.11)
By combining Eq. (3.10) and Eq. (3.11) together, the overall variance of ^SRTjkl is
Var(^SRTjkl ) =
1
nj

(2AjBk + 
2
AjBk
)
(1  Pk)
Pk
+ (1  )(2AjCl + 2AjCl)
(1 Ql)
Ql
+ (2AjBk + 
2
AjBk
) + (1  )(2AjCl + 2AjCl)
  AjBk + (1  )AjCl	2 
=
1
nj

(2AjBk + 
2
AjBk
)
1
Pk
+ (1  )(2AjCl + 2AjCl)
1
Ql
  AjBk + (1  )AjCl	2 : (3.12)
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For the equal probability of the maintenance treatment (i.e. Pk = Ql = 1=2), the variance
of the estimator is
Var(^SRTjkl ) =
1
nj

2
n
(2AjBk + 
2
AjBk
) + (1  )(2AjCl + 2AjCl)
o
  AjBk + (1  )AjCl	2 
3.3.3 Estimation with Probability-adjusted-weights in Sequentially Random-
ized Trials
Another estimator commonly used in SRT is the probability-adjusted inverse-probability-
weighted estimator (Lunceford et al. [2002]). We will call this estimator as the probability-
adjusted estimator, thereafter. The probability-adjusted estimator is expressed as
^SRTPAjkl =
"
njX
i=1

RiIi(Bk)
Pk
+
(1 Ri)Ii(Cl)
Ql
# 1 njX
i=1

RiIi(Bk)
Pk
+
(1 Ri)Ii(Cl)
Ql

Yi
=
njX
i=1
WkiYi +
njX
i=1
WliYi
=Gnk +Gnl;
where
Wki =
QlRiIi(Bk)
Ql
Pnj
i=1RiIi(Bk) + Pk
Pnj
i=1(1 Ri)I(Cl)
;
and
Wli =
Pk(1 Ri)Ii(Cl)
Pk
Pnj
i=1RiIi(Cl) +Ql
Pnj
i=1(1 Ri)I(Bk)
:
Note that
EfWkijRi; Y (AjBk)g  QlRiPk
QlPk
Pnj
i=1Ri +QlPk
Pnj
i=1(1 Ri)
 Ri
nj
:
Therefore, E(Wki)  =nj and similarly, E(Wli)  (1  )=nj.
Unbiasedness of this estimator is shown as follows. We can write
E(^SRTPAjkl ) =E(Gnk) + E(Gnl): (3.13)
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For the rst part of Eq. (3.13),
E(Gnk) =E
 
njX
i=1
WkiYi
!
(By consistency assumption)
=E
(
njX
i=1
WkiYi(AjBk)
)
=E
"
njX
i=1
Yi(AjBk)EfWkijRi; Yi(AjBk)g
#
E
(
njX
i=1
Ri
nj
Yi(AjBk)
)
=
1
nj
njX
i=1
E [RiEfYi(AjBk)jRig]
=
1
nj
njX
i=1
AjBk
=AjBk :
Similarly, E(Gnl) = (1  )AjCl . Then we have
E(^SRTPAjkl ) = AjBk + (1  )AjCl = AjBkCl :
To derive the variance of ^SRTPAjkl , we note that
Var(^SRTPAjkl ) =Var(Gnk) + Var(Gnl) + 2cov(Gnk; Gnl): (3.14)
Consider the rst part of the Eq. (3.14) rst,
Var(Gnk) =Var
 
njX
i=1
WkiYi
!
=Var
(
njX
i=1
WkiYi(AjBk)
)
=
njX
i=1
Var fWkiYi(AjBk)g :
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Then,
VarfWkiYi(AjBk)g =Var[EfWkiY (AjBk)jRi; Yi(AjBk)g]
+ E[VarfWkiYi(AjBk)jRi; Yi(AjBk)g]
E
(
Ri
nj
Yi(AjBk)
2)
  E

Ri
nj
Yi(AjBk)
2
+ E[Y 2i (AjBk)VarfWkijRi; Yi(AjBk)g]:
The conditional variance of Wki can be approximated as
VarfWkijRi; Yi(AjBk)g  EfW 2kijRi; Yi(AjBk)g  
Ri
n2j
 E
264 RiIi(Bk)Q2l =n2jn
Ql
P
RiIi(Bk)
nj
+ Pk
P
(1 Ri)Ii(Cl)
nj
o2
375  Ri
n2j
 E

RiIi(Bk)Q
2
l =n
2
j
fQlPk + Pk(1  )Qlg2

  Ri
n2j
 Ri
n2j
1
Pk
  Ri
n2j
 Ri
n2j

1  Pk
Pk

:
Therefore,
VarfWkiY (AjBk)g  1
n2j
n
(2AjBk + 
2
AjBk
)  22AjBk
o
+ E

Y 2i (AjBk)
Ri
n2j
1  Pk
Pk

 1
n2j
n
(2AjBk + 
2
AjBk
)  22AjBk
o
+
1
n2j

1  Pk
Pk

(2AjBk + 
2
AjBk
)

=

n2j

1 +
1  Pk
Pk

(2AjBk + 
2
AjBk
)  2AjBk

=

n2j

1
Pk
(2AjBk + 
2
AjBk
)  2AjBk

:
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Similarly,
VarfWliY (AjCl)g 1  
n2j

1
Ql
(2AjCl + 
2
AjCl
)  (1  )2AjCl

:
For the covariance term,
Cov(Gnk; Gnl) =E(Gnk; Gnl)  E(Gnk)E(Gnl)
=E
njX
i=1
njX
j=i
(WkiWljYiYj)  AjBk(1  )AjCl
=
nj(nj   1)
n2j
fAjBk(1  )AjClg   AjBk(1  )AjCl
=  1
nj
AjBk(1  )AjCl :
Therefore, the variance for probability-adjusted SRT is
Var(^SRTPAjkl ) 
1
nj


Pk
(2AjBk + 
2
AjBk
) +
(1  )
Ql
(2AjCl + 
2
AjCl
)
   AjBk + (1  )AjCl2: (3.15)
For the equal probability of the maintenance treatment, the variance of the estimator is
Var(^SRTPAjkl ) 
1
nj

2

(2AjBk + 
2
AjBk
) + (1  )(2AjCl + 2AjCl)

   AjBk + (1  )AjCl2:
From Eq. (3.12) and Eq. (3.15), we see that, for suciently large n, the variance
of the IPW and probability-adjusted estimators have the same variance. Therefore, when
comparing SRT to URT, we will use the probability-adjusted estimator. The variance in
Eq. (3.15) can be estimated by replacing the parameters with the corresponding sample
estimates. For example,
^2AjBk =
Pnj
i=1 I(Bk)
n
Y  
Pnj
i=1 I(Bk)YPnj
i=1 I(Bk)
o
Pnj
i=1 I(Bk)  1
:
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An analogous estimator can be used for ^2AjCl . Instead of estimating sample variances in-
dividually, we use the fact that estimators (^SRTjkl and ^
SRTPA
jkl ) are the solutions to the
estimating equations
nX
i=1
 i(
SRT
jkl ) =
njX
i=1

RiIi(Bk)
Pk
+
(1 Ri)Ii(Ckl)
Ql

Yi   SRTjkl

= 0;
and
nX
i=1
 i(
SRTPA
jkl ) =
njX
i=1

RiIi(Bk)
Pk
+
(1 Ri)Ii(Ckl)
Ql

(Yi   SRTPAjkl )

= 0;
respectively. Then, the variances could be estimated by so-called sandwich variance estima-
tor.
var(^SRTjkl ) =

1
nj

B(^SRTjkl )
A(^SRTjkl )
2
;
where An(x) is the empirical estimate of A(x) =  E
h


f i()g
i
j=x = 1 and Bn(x) =P
 2i (x)
nj
. Similarly, Var(^SRTPAjkl ) also can be estimated.
The covariance of the two estimators can be estimated in a similar manner. For example,
for ^111 and ^112, the covariance is
cov(^SRT111 ; ^
SRT
112 ) =n
 2
1
X
 i(
SRT
111 ) i(
SRT
112 ):
19
3.3.4 Hypothesis Testing
To test hypotheses regarding the strategy-specic means, we construct test statistics based
on Wald-type tests. For example, to test the dierence among 111, 112, 121 and 122,
constructed test statistic as follows :
^ =
h
^111 ^112 ^121 ^122
i
Ce =
26664
1 0  1 0
0 1 0  1
1  1 0 0
37775
e =
26666664
var(^111) cov(^111; ^112) cov(^111; ^121) cov(^112; ^122)
cov(^112; ^111) var(^112) cov(^112; ^121) cov(^112; ^122)
cov(^121; ^111) cov(^121; ^112) var(^121) cov(^121^122)
cov(^122; ^111) cov(^122; ^112) cov(^122; ^121) var(^122)
37777775
Z2 = ^T  CeT  [Ce  e  CeT ] 1  Ce  ^;
where T stands for transpose of a matrix. This statistic can be approximated by a 2
distribution with 3 degree of freedom under the null hypothesis of no dierence. Similarly,
test statistics for other hypotheses testing can be constructed.
3.4 SIMULATION STUDY
The true population in the simulation can be described in terms of the distribution of coun-
terfactual variables. For each individual i in the population, assume that Yi(AjBk) and
Yi(AjCl) are individually normally distributed with mean AjBk and variance 
2
AjBk
, and
mean AjCl and variance 
2
AjCl
respectively, j; k; l = 1; 2. The response indicator Ri was
assumed to follow a Bernoulli distribution with probability of success R1 for the initial
treatment A1 and R2 for A2.
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We repeatedly (1000) sampled data from this population by using two forms of designs
- URT and SRT. In the URT design, n individuals are randomized with equal probability to
8 dierent strategies A1B1C1; A1B1C2; : : : ; A2B2C2. In the SRT, we randomized n patients
rst to two induction treatments A1 and A2 with probabilities A1 and A2 respectively (A1
+ A2 = 1). For simplicity, we use A = A1 = A2 = 1=2, throughout the study. In both
designs, the observed outcome was generated from the counterfactual distributions using
the formula (3.8). The response status Ri for the i
th patient was generated according to a
Bernoulli distribution with probability of success . When Ri=1, we randomly assigned the
patient to B1(B2) with probability P1(P2) (P1 + P2 = 1). Similarly, patients with Ri = 0
where randomized to C1(C2) with probability Q1(Q2) (Q1 + Q2 = 1).
We considered many dierent simulation scenarios by varying the values of population
parameters AjBk , 
2
AjBk
, AjCl , 
2
AjCl
, R1 , R2 , Pk and Ql, j; k; l = 1; 2. On the other hand,
the rst treatment assignment probability, A is set to 1=2 for all scenarios. Therefore,
number of samples for both rst treatments A1 and A2 are equal.
The rst four scenarios represented here assumes that AjBk=AjCl = 15, j; k; l = 1; 2,
and 2AjBk = 6, j; k = 1; 2, and 
2
AjCl
= 8, j; l = 1; 2. In these situations, the eight strategy
means are all equal to 15, i.e., A1B1C1 = A1B1C2 = A1B2C1 = A1B2C2 = A2B1C1 = A2B1C2
= A2B2C1 = A2B2C2=15. In our rst simulation scenario, we assumed R1 = R2 = P1 =
Q1 = 1=2. Then R1 and R2 are adjusted to see the change for other scenarios.
Table 1 summarizes the results of the simulation under designs from scenario 1-4, where
all the strategy means are identical. The table lists the estimated strategy-specic means
(Est.), Monte Carlo standard error (SE), and the relative bias (RB %). It also provides
the coverage probability (CP) of 95% condence interval based on normality assumptions.
In addition, the table provides type I error rates for testing three hypotheses, namely H1 :
strategy means are identical for strategies sharing the same rst stage treatment A1 (A1B1C1
= A1B1C2 = A1B2C1 = A1B2C2), H2 : strategy means are identical for strategies sharing the
same rst stage treatment A2 (A2B1C1 = A2B1C2 = A2B2C1 = A2B2C2) and H3 : strategy
means are identical for all strategies (H3 : A1B1C1 = A1B1C2 = A1B2C1 = A1B2C2 = A2B1C1
= A2B1C2 = A2B2C1 = A2B2C2).
From the results in Table 1, we see that both URT and SRT produce unbiased estima-
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tors of strategy means under the same sample size. Absolute relative biases were less than
0:7% for URT estimator and less than 0:5% for probability-adjusted estimator from the SRT.
Standard errors of estimators are generally lager for the URT estimators as compared to the
probability-adjusted estimator. In most cases, URT estimator fails to meet nominal coverage
level for the 95% Wald condential interval. On the other hand, probability-adjusted estima-
tor provides coverage probabilities close to the nominal level. In most cases, rejection rates
for the true null hypothesis match the nominal type I error rate of 5% for the probability-
adjusted estimator in the SRT design, whereas for URT, the observed type I error rate were
always larger than the nominal level. This was true irrespectively of the hypotheses being
tested. And adjusting response rate does not change the results.
In the next four scenarios, we assume that AjB1 = 15, AjC1 = 20, AjB2 = 22, AjC2 =
15, j=1; 2, and 2AjBk=6, j; k=1; 2, and 
2
AjCl
=8, j; l=1; 2 to test alternative hypothesis that
all strategies have dierent means. In Tables 2(a) and 2(b), we assume that R1 = R2 = P1
= Q1 = 1=2 with sample sizes 150 and 200, respectively. In the next two scenarios (Tables
2(c) and 2(d)), response rates, R1 and R2 are adjusted to 0:1, 0:5 and 0:8 with n = 200.
Table 2 provides the powers for testing hypotheses to detect mean dierence in addition
to estimated strategy-specic means (Est.), MC standard error (SE), the relative bias (RB
%) and the coverage probability (CP) of 95% condence interval. Here, we use the same three
hypotheses dened in Table 1. As can be seen from Table 2, both estimators are approxi-
mately unbiased. Relative biases were less than 0:8% for URT estimator and less than 0:6%
for probability-adjusted estimator from the SRT. Standard errors of probability-adjusted
estimator in SRT are smaller than the estimator in URT. And the probability-adjusted es-
timator in SRT achieves the nominal level of coverage probabilities and almost over 95% of
power of the hypothesis to detect mean dierence while coverage probabilities of the esti-
mator in URT are less than the nominal level and its power is about 70%. Similar to the
Table 1, adjusting response rate does not change the results. We note that both show better
performance, such as smaller relative bias, smaller standard errors, smaller power and higher
coverage probabilities with larger sample size.
Table 3 shows how the proportions of treatment assignment of Bk or Cl aect the esti-
mates. Small probability of receiving Bk (i.e., Pk  0:5) makes the variance of the ^j1k larger
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and large proportion of receiving Bk (i.e., Pk  0:5) makes the variance of ^j2k larger. This
is analogous to the Ql. From this scenario, we note that the probability-adjusted estimators
in SRT for Bk have smaller standard errors when Pk > 0:5 during the simulation study. This
applied to the Cl with Ql similarly.
Overall, the simulation studies showed that the both estimators are approximately un-
biased. The performance of the probability-adjust estimator in SRT was better than the
estimator in URT in terms of unbiasedness, eciency and power.
3.5 DISCUSSION
In this chapter, we have compared the estimators in up-front and sequential randomization
trials using a statistical inferential approach. The estimator in URT can be obtained directly.
For SRT, we employed the IPW estimator (Robins et al. [1994]) and the probability-adjusted
estimator (Lunceford et al. [2002]). Using the sequential randomization assumption, we
showed unbiasedness of estimators. Our simulation results indicated that all estimators are
approximately unbiased. However, the probability-adjusted estimator in SRT has smaller
standard errors and higher power than the estimator in URT. During this study, we also
noted that the eciency of the estimators could be related to the maintenance treatment
proportion. Because the assigned sample size for a specic treatment strategy is aected by
this proportion. In conclusion, the probability-adjusted estimator in sequential randomized
trial performed better than the estimator in up-front randomized trial in terms of eciency
of the estimators and the power of statistical hypothesis testing.
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Table 1: Simulation results of estimation with the same means
(a) n = 150, A = 0:5 , R1 = 0:5 ,R2 = 0:5, Pk = 0:5, Ql = 0:5
Estimator in URT Probability-adjusted estimator in SRT
Policy True Est. SE RB(%) CP Type I Est. SE RB(%) CP Type I
A1B1C1 15.0 15:0 1:42  0:1 0:89
0:0741
15:0 1:14 0:0 0:94
0:0651
A1B1C2 15.0 14:9 1:42 0:4 0:89 15:1 1:14  0:3 0:94
A1B2C1 15.0 15:0 1:41 0:3 0:89 15:0 1:14 0:3 0:93
A1B2C2 15.0 15:0 1:41 0:0 0:90 15:0 1:14  0:1 0:94
A2B1C1 15.0 15:0 1:76 0:5 0:89
0:0732
15:0 1:13 0:2 0:93
0:0692
A2B1C2 15.0 15:0 1:76 0:4 0:89 15:0 1:14 0:3 0:94
A2B2C1 15.0 15:0 1:77  0:1 0:89 15:0 1:13  0:2 0:94
A2B2C2 15.0 15:0 1:76 0:2 0:88 15:0 1:14  0:0 0:94
0:0573 0:0533
(b) n = 150, A = 0:5 , R1 = 0:1 ,R2 = 0:5, Pk = 0:5, Ql = 0:5
A1B1C1 15.0 15:0 1:84  0:2 0:92
0:0901
15:0 1:27  0:3 0:94
0:0421
A1B1C2 15.0 15:0 1:82  0:1 0:92 15:0 1:26 0:3 0:95
A1B2C1 15.0 15:0 1:85  0:0 0:93 15:0 1:27  0:1 0:94
A1B2C2 15.0 14:9 1:85 0:7 0:94 14:9 1:26 0:5 0:94
A2B1C1 15.0 14:9 1:77 0:4 0:93
0:0712
15:0 1:14  0:1 0:93
0:0772
A2B1C2 15.0 15:1 1:74  0:4 0:92 15:0 1:13  0:0 0:94
A2B2C1 15.0 15:1 1:78  0:5 0:93 15:0 1:14 0:1 0:93
A2B2C2 15.0 15:0 1:77  0:2 0:95 15:0 1:13 0:0 0:92
0:0733 0:0373
(c) n = 150, A = 0:5 , R1 = 0:5 ,R2 = 0:9, Pk=0.5, Ql = 0:5
A1B1C1 15.0 15:0 1:51  0:1 0:92
0:0691
15:0 1:14  0:0 0:93
0:0571
A1B1C2 15.0 15:1 1:51  0:9 0:90 15:0 1:14  0:2 0:94
A1B2C1 15.0 15:0 1:51 0:2 0:91 15:0 1:14 0:2 0:92
A1B2C2 15.0 15:0 1:52 0:2 0:92 15:0 1:14 0:1 0:95
A2B1C1 15.0 15:0 1:90  0:1 0:90
0:0662
15:0 1:01 0:1 0:93
0:0522
A2B1C2 15.0 15:0 1:89  0:0 0:90 15:0 1:01 0:0 0:93
A2B2C1 15.0 15:0 1:88  0:0 0:93 15:0 1:00  0:0 0:95
A2B2C2 15.0 15:0 1:89 0:1 0:90 15:0 1:00  0:1 0:95
0:0493 0:0363
(d) n = 150, A = 0:5 , R1 = 0:2 ,R2 = 0:9, Pk = 0:5, Ql = 0:5
A1B1C1 15.0 15:0 1:75 0:1 0:93
0:0731
15:0 1:24  0:3 0:95
0:0561
A1B1C2 15.0 15:0 1:77  0:1 0:93 15:0 1:24  0:3 0:94
A1B2C1 15.0 15:0 1:76  0:0 0:92 15:0 1:24  0:2 0:94
A1B2C2 15.0 15:0 1:76 0:2 0:91 15:0 1:24  0:1 0:9
A2B1C1 15.0 15:0 1:33 0:3 0:94
0:0672
15:0 1:00  0:2 0:93
0:0602
A2B1C2 15.0 15:0 1:32  0:0 0:92 15:0 1:00  0:1 0:94
A2B2C1 15.0 15:0 1:33  0:1 0:93 15:0 1:01  0:2 0:92
A2B2C2 15.0 15:0 1:33  0:2 0:93 15:0 1:00  0:1 0:93
0:0573 0:0443
1H1 : A1B1C1 = A1B1C2 = A1B2C1 = A1B2C2 ,
2H2 : A2B1C1 = A2B1C2 = A2B2C1 = A2B2C2 ,
3H3 : A1B1C1 = A1B1C2 = A1B2C1 = A1B2C2 = A2B1C1 = A2B1C2 = A2B2C1 = A2B2C2
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Table 2: Simulation results of estimation with the dierent means
(a) n = 150, A = 0:5 , R1 = 0:5 ,R2 = 0:5, Pk = 0:5, Ql = 0:5
Estimator in URT Probability-adjusted estimator in SRT
Policy True Est. SE RB(%) CP Power Est. SE RB(%) CP Power
A1B1C1 17:5 17:5 1:94 0:1 0:88
0:4541
17:6 1:47  0:6 0:91
0:7831
A1B1C2 15.0 15:1 1:84  0:3 0:91 15:1 1:39  0:6 0:93
A1B2C1 21.0 21:2 1:87  0:7 0:88 21:0 1:40  0:1 0:92
A1B2C2 18.5 18:5 2:03 0:1 0:88 18:5 1:39 0:1 0:92
A2B1C1 17.5 17:5 1:70  0:3 0:89
0:4452
17:5 1:46 0:2 0:92
0:8122
A2B1C2 15.0 15:0 1:61  0:3 0:89 15:0 1:38  0:1 0:93
A2B2C1 21.0 21:1 1:62  0:3 0:88 21:1 1:40  0:3 0:92
A2B2C2 18.5 18:6 1:82  0:4 0:91 18:6 1:54  0:5 0:90
0:5733 0:9403
(b) n = 200, A = 0:5 , R1 = 0:5 ,R2 = 0:5, Pk = 0:5, Ql = 0:5
A1B1C1 17.5 17:5 1:49 0:1 0:95
0:7201
17:5 1:05 0:1 0:92
0:9911
A1B1C2 15.0 15:0 1:41 0:3 0:94 15:0 0:99 0:3 0:94
A1B2C1 21.0 21:0 1:42  0:0 0:94 21:0 0:99  0:2 0:93
A1B2C2 18.5 18:5 1:57 0:1 0:94 18:5 1:10  0:1 0:93
A2B1C1 17.5 17:4 1:60 0:7 0:94
0:7062
17:5 1:05 0:1 0:93
0:9822
A2B1C2 15.0 15:0 1:51 0:0 0:92 15:0 0:99 0:3 0:94
A2B2C1 21.0 20:9 1:52 0:4 0:92 21:0 1:01 0:0 0:95
A2B2C2 18.5 18:5 1:68 0:2 0:93 18:5 1:11 0:1 0:94
0:8743 1:0003
(c) n = 200, A = 0:5 , R1 = 0:5 ,R2 = 0:8, Pk = 0:5, Ql = 0:5
A1B1C1 17.5 17:6 1:41  0:3 0:91
0:7211
17:5 1:05  0:1 0:94
0:9771
A1B1C2 15.0 15:1 1:35  0:3 0:92 15:1 0:99  0:4 0:94
A1B2C1 21.0 21:0 1:34  0:0 0:91 21:0 1:00 0:2 0:93
A1B2C2 18.5 18:4 1:49 0:1 0:92 18:5 1:13  0:0 0:94
A2B1C1 16.0 16:0 1:33 0:2 0:92
0:9652
16:0 0:95  0:1 0:95
0:9992
A2B1C2 15.0 15:0 1:27  0:0 0:91 15:0 0:91  0:0 0:94
A2B2C1 21.6 21:6 1:27  0:0 0:93 21:6 0:91 0:1 0:95
A2B2C2 20.6 20:6 1:38 0:1 0:92 20:6 0:99 0:1 0:95
0:9763 0:9993
(d) n = 200, A = 0:5 , R1 = 0:1 ,R2 = 0:5, Pk = 0:5, Ql = 0:5
A1B1C1 19.5 19:5 1:58  0:2 0:92
0:7021
19:5 1:12 0:1 0:94
0:8401
A1B1C2 15.0 14:9 1:53 0:5 0:93 15:0 1:10 0:3 0:94
A1B2C1 20.2 20:2 1:54  0:1 0:92 20:2 1:10  0:1 0:94
A1B2C2 15.7 15:7 1:59 0:8 0:91 15:7 1:10 0:2 0:95
A2B1C1 17.5 17:6 1:27  0:4 0:93
0:7332
17:5 1:05 0:1 0:94
0:9862
A2B1C2 15.0 15:1 1:19  0:5 0:94 15:0 1:00 0:1 0:93
A2B2C1 21.0 21:0 1:20  0:2 0:94 21:0 1:00  0:1 0:94
A2B2C2 18.5 18:5 1:40 0:3 0:94 18:5 1:11  0:0 0:93
0:8753 0:9983
1H1 : A1B1C1 = A1B1C2 = A1B2C1 = A1B2C2 ,
2H2 : A2B1C1 = A2B1C2 = A2B2C1 = A2B2C2 ,
3H3 : A1B1C1 = A1B1C2 = A1B2C1 = A1B2C2 = A2B1C1 = A2B1C2 = A2B2C1 = A2B2C2
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Table 3: Simulation results of estimation by adjusting probability of maintenance treatment
n = 200, A = 0:5 , R1 = R2 = 0:5, Pk = 0:9, Ql = 0:5
Estimator in URT Probability adjusted estimator in SRT
Policy True Est. SE RB(%) CP Power Est. SE RB(%) CP Power
A1B1C1 17.5 17:5 1:51 0:2 0:95
0:7211
17:5 0:97  0:2 0:95
0:8281
A1B1C2 15.0 15:0 1:43 0:1 0:95 15:0 0:91 0:2 0:94
A1B2C1 21.0 21:0 1:42  0:2 0:92 21:0 1:52 0:2 0:91
A1B2C2 18.5 18:5 1:58  0:2 0:94 18:3 1:72 0:8 0:89
A2B1C1 17.5 17:5 1:60  0:3 0:94
0:7532
17:5 0:96  0:2 0:93
0:8552
A2B1C2 15.0 15:0 1:52 0:3 0:94 15:1 0:91  0:4 0:94
A2B2C1 21.0 21:0 1:52  0:2 0:93 21:0 1:50  0:1 0:90
A2B2C2 18.5 18:5 1:68 0:1 0:93 18:4 1:69 0:5 0:89
0:8963 0:9693
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4.0 NONPARAMETRIC INFERENCE ON MEDIAN RESIDUAL LIFE
FUNCTION IN SEQUENTIALLY RANDOMIZED TRIALS
4.1 INTRODUCTION
Sequentially randomized trials (SRT) are eective methods for comparing ATSs. In SRT,
patients are randomized sequentially to treatment options as the trial progresses and patients
move from one stage to another.
Figure 2: An example of Sequentially Randomization Trial from Cancer and Leukemia group
B
Figure 2 shows an example of SRT with two stages, drawn from a leukemia study protocol
from CALGB co-operative group. At entry, patients are randomized to one of the two rst-
stage treatments standard chemotherapy(A1) or standard chemotherapy plus granulocyte-
macrophage colony-stimulating factor(GM-CSF)(A2). Once the patient achieves complete
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remission, he/she is randomized to the second-stage treatments cytrabine(B1) or cytrabine
plus mitoxantrone(B2). This SRT allows comparison of 4 treatment strategies AjBk, j; k =
1; 2, where the strategy AjBk is dened as \Treat with Aj followed by Bk if a response to Aj
is observed "(Lunceford et al. [2002]). Note that a patients belonging to any of the following
scenarios is considered to be treated with strategy AjBk (consistent with strategy AjBk) :
1. Patient received Aj, and did not respond.
2. Patient received Aj, responded, and received Bk at the second stage.
The objective would be to assess which of these four strategies AjBk; j; k = 1; 2 results in
the best benet for the patients. In survival analysis, the best benet would be measured
by longest survival time. The sample mean is the most common statistics in terms of
summarizing the survival distributions. Survival probabilities at a xed point of time or
median survival are also used to summarize the data.
The estimation of mean survival time in SRT, especially in two-stage design, has been
discussed extensively in the literature. Lunceford et al. [2002] proposed estimators for the
survival distribution and mean restricted survival time under dierent treatment strategies
using the concept of inverse-probability-weighting (IPW) (Robins et al. [1994]). Locally
ecient estimators for survival distribution in two-stage design settings were introduced by
Wahed and Tsiatis [2004], Wahed et al. [2006] for complete and right censored cases. The
improvement in eciency of these estimators was achieved through the use of additional
information from auxiliary covariates. Guo [2005] proposed a weighted risk set estimator
(WRSE) for the survival distribution. Even though the sample mean is the most commonly
used index to summarize a distribution, this may not be a good summary representative of
the overall distribution when the data are highly skewed. In such a case, percentiles can be
a good index outlining the distribution instead of means.
In addition to percentile of the distribution (including median), the median residual life
function (MERL function) is frequently used for the time-to-event data. A MERL function
is the median of the remaining life time at a specic time point. For overall survival T , the
median residual lifetime at time t0 is dened as
(t0) = median(T   t0jT  t0);
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where median(XjY ) stands for the median of the conditional distribution of X given Y . In
other words, (t0) is the median time for those who survived beyond time t0 in the popula-
tion. The median residual lifetime is stable since it is not aected by outliers such as very
long durations of survival time. In the case with censored data, the use of a median for the
residual lifetime not only exhibits a better location estimate than its mean but also shows
less sensitivity to skewed distributions. The minimum of observed survival probability of the
residual life distribution should be smaller than the 0:5, so that the median residual lifetime
can be dened under censoring (Schmittlein et al. [1981]).
Various methods have been proposed in the literature to estimate the median residual
lifetimes for one and two sample cases. Haines et al. [1974] introduced a general concept of
the -percentile residual life function (0 <  < 1). Schmittlein et al. [1981] established a
general concept of MERL function exploring non-uniqueness of the corresponding life distri-
bution. Csorgo et al. [1987] proposed a 100(1 p)th percentile residual lifetime estimator for
complete data, whereas Chung [1989] extended this idea to censoring cases. The nonparamet-
ric estimator of 100(1  p)th percentile residual lifetime was proposed by Feng et al. [1991],
where inverse function of the Kaplan-Meier curve was used. Jeong et al. [2008] introduced a
test statistic to compare two median residual lifetimes at a xed time point. However, these
methods cannot be applied to estimate median residual lifetime for treatment strategies in
two-stage designs as they do not account for sequential randomization structure.
In this study, we aim to develop methods for nonparametric estimation of strategy-
specic median residual lifetime from two-stage randomization designs. Our method uses
the marginal mean models for survival data introduced by Lunceford et al. [2002] for se-
quentially randomized trials. We also use inverse-probability weighted estimating equations
directly for this purpose.
Notation used throughout this chapter is described in Section 4.2. Estimation of MERL
function using dierent approaches is discussed in Section 4.3. We present a simulation study
to demonstrate the performance of proposed methods in Section 4.4. Then, we apply these
methods to a leukemia data set in Section 4.5.
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4.2 NOTATION AND ASSUMPTIONS
We consider the two-stage design described in the previous section. Our development of
methods borrows the idea of counterfactual variables from the causal inference literature
(Holland [1986]). Consider only the population that receives A1 as the initial treatment
(development for the population receiving A2 is analogous). For the i
th individual in the
population, let Ri be the response indicator: Ri = 1 if a response to the rst-stage treatment
is achieved, 0 otherwise. If the patient did not respond, his/her survival time is denoted by
TNRi. Let T

ki be the post-response survival time for patient i if the patient had responded
and received Bk as the maintenance treatment. Let Tai be the time to the starting of the
second-stage treatment, if the ith patient proceeded to the second stage. Thus, under the
strategy A1Bk, the overall survival time for patients i can be dened as
Tki = (1 Ri)TNRi +Ri(Tai + T ki); k = 1; 2:
Note that, T1 and T2 both cannot be observed for the same patient since a patient either
does not receive any maintenance treatment, or receives only one of the two maintenance
treatments, B1 or B2. For such, these variables are referred to as potential outcomes or
counterfactuals (Holland [1986]). The interest lies in estimating the MERL function for the
strategy A1Bk or equivalently for the overall survival Tki. Now, the survival time for the
ith patient, Ti, if observed for the i
th individual, can be expressed in terms of T1 and T2 by
means of the consistency assumption (Cole [2009]) as follows.
Ti = Z1iT1i + Z2iT2i; (4.1)
where Zki is the Bk treatment assignment indicator, i.e. Zki = 1 if the i
th patient was
assigned to treatment Bk, 0 otherwise. Note that, Eq. (4.1) can alternatively be expressed
as,
Ti = (1 Ri)TNRi +RifTai + Z1iT 1i + Z2iT 2ig:
Unfortunately, Ti also may not be observed for the i
th individual, since it may be cen-
sored. The observed data from a two-stage design described in Figure. 2 can be denoted
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by (Ri; RiZki; Ui;i) i = 1:::n; k = 1; 2, where Ri and Zki are as dened before, i is the
complete case indicator, and Ui is the event (survival or censoring) time. If Ci is used to
denote the censoring time for the ith individual in the sample, then Ui = min(Ti; Ci) and
i = I(Ti < Ci). Note that, in practice, patients may be censored prior to a response being
observed; such patients are historically treated as non responders in the analysis. We assume
that censoring does not depend on Ti or any other observed or counterfactual data. Denote
by K(t) the survival distribution function of censoring time Ci, i.e., K(t) = P (Ci  t). Let
1 = P (Z1i = 1jRi = 1) and 2 = 1   1 denote the probability of receiving treatment B1
or B2, respectively. Further let Sk(t) = P (Tk > t) denote the survival probability at time t
under strategy A1Bk for k = 1; 2.
Again, our goal is to nd an estimator of the MERL function under strategy A1Bk for
k = 1; 2. In other words, we would like to estimate k(t0), where
k(t0) = median(Tk   t0jTk > t0): (4.2)
4.3 ESTIMATION OF THE MEDIAN RESIDUAL LIFE FUNCTION
We rst express k(t0) as a function of Sk(t0) so that the median residual lifetime can be
estimated indirectly from the estimated survival curve. The MERL function dened in Eq.
(4.2) can be expressed as P (Tk   t0  k(t0)jTk  t0) = 12 , thereby suggesting that
k(t0) = S
 1
k

1
2
Sk(t0)

  t0; (4.3)
where S 1k (u) is the inverse of the survival function at u, i.e., S
 1
k (u) = infft : Sk(t) < ug.
Thus, one way to estimate k(t0) is to estimate the survival distribution Sk(t0) and use Eq.
(4.3) to obtain ^k(t0) as
^
(1)
k (t0) =S^
 1
k

1
2
S^k(t0)

  t0; (4.4)
where S^k(t) is a consistent estimator of Sk(t) (Feng et al. [1991], Jeong et al. [2008]). As
long as the largest observation in the sample is uncensored, the MERL function can be
appropriately estimated.
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One way to estimate the survival curve for a given strategy A1Bk is the probability-
adjusted inverse-probability-weighted estimator dened as:
S^k(t0) =
(
nX
i=1
iQki
K^(Ui)
) 1( nX
i=1
iQki
K^(Ui)
I(Ui > t0)
)
; (4.5)
where, K^(Ui) is the Kaplan-Meier estimator of K(t) and Qki = 1   Ri + RiZkik , k = 1; 2
is the weight function. This function assigns appropriate weight to each observation that
is consistent with the strategy A1Bk. In the estimation of the survival function Sk, every
uncensored Ui is weighted by
1
K(Ui)
to reect the fact that there were P (CiUi)
P (Ci>Ui)
= 1
K(Ui)
  1
expected censored individuals in the population at time Ui. Therefore, the response for an
uncensored individual counts for him/herself and additional censored individual 1
K(Ui)
  1.
The weightsQki are dened based on the fact that patients who did not respond are consistent
with both strategies A1B1 and A1B2, and those who responded, only a portion of them are
treated with A1B1 (A1B2) with probability 1 (2). Thus, for the treatment strategy A1B1,
Q1i = 0 if individual i received B2 treatment (i.e., Ri = 1 and Zi = 0), while Q1i = 1 if
Ri = 0, and Q1i = 
 1
1 if Ri = 1 and Zi = 1 to reect the weights due to randomization.
Similarly, when an individual receives a treatment which is consistent with the treatment
strategy A1B2, Q2i acts as a weight.
Lunceford et al. [2002] showed that the estimator S^k(t0) dened by Eq. (4.5) is a con-
sistent and asymptotically normal estimator with mean Sk(t0) and variance 
2
k(t0) that can
be estimated by
^2k(t0) =
1
n
"
1
n
nX
i=1
iQki
K^(Ui)
n
I(Ui > t0)  1 + S^k(t0)
o2
+
Z L
0
dN c(u)
K^(u)Y (u)
E^fLki(t; u)g2
#
;
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whereZ L
0
dN c(u)
K^(u)Y (u)
E^fLki(t; u)g2
=
nX
j=1
(
1 j
K^(Uj)Y (Vj)

1
n
nX
i=1
i
n
Qki
 
I(Ui > t0)  1 + S^k(t0)

  G^k(t; Ui)
o2 I(Ui  u)
K^(Ui)
)
,
G^ki(t; u) =
1
nS^(u)
 nX
i=1
iQki
 
I(Ui > t0)  1 + S^k(t0)
I(Ui  u)
K^(Ui)

:
Here, N c(u) =
P
N ci (u) =
P
I(Ui < u;i = 0) and Y (u) =
P
Yi(u) =
P
I(Ui  u).
4.3.1 Survival Function Based Estimator
Substituting Eq.(4.5) in Eq.(4.4), we obtain the rst estimator for the MERL function. This
estimator will be referred to as survival function based (SFB) estimator, ^
(1)
k (t0). To calculate
the variance of this estimator, we rst note that ^
(1)
k (t0) satises S^k(t0+^
(1)
k (t0))  12 S^k(t0) = 0.
Let us denote the left hand side of the above equation by  k(^
(1)
k (t0)). Expanding  k(^
(1)
k (t0))
around k(t0), we obtain,
 k(^
(1)
k (t0))   k(k(t0)) + (^(1)k (t0)  k(t0))
 k(k(t0))
k(t0)
:
Assuming sucient regularity, it follows that variance of ^k(t0) could be approximated by
Var(^
(1)
k ) 
var[ k(^
(1)
k (t0))]
 k(k(t0))
k(t0)
2 :
Note that,
 k()

=  fk(t0 + );
leading to
Var(^
(1)
k (t0)) 
var( k(^
(1)
k (t0)))
f2k (t0 + ^
(1)
k (t0))
; (4.6)
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where fk() is the density function of Tk, which can be estimated by using nonparametric
smoothing technique such as the kernel density estimator. To estimate the variance in Eq.
(4.6), we rst note that  k(^
(1)
k (t0)) can be written as
(
nX
i=1
iQki
K^(Ui)
) 1( nX
i=1
iQki
K^(Ui)
hfUi; ^(1)k (t0)g
)
;
where hfUi; g = I(Ui >  + t0)  12I(Ui > t0). Following Lunceford et al. [2002], we obtain
a consistent estimator of Var( ^k(^
(1)
k (t0)) as follows:
var( ^k(^
(1)
k (t0))) =
1
n
"
1
n
nX
i=1
iQki
K^(Ui)
n
h(Ui)
o2
+
Z L
0
dN c(u)
K^(u)Y (u)
E^fLki(t; u)g2
#
; (4.7)
whereZ L
0
dN c(u)
K^(u)Y (u)
E^fLki(t; u)g2
=
nX
j=1
(
1 j
K^(Uj)Y (Vj)

1
n
nX
i=1
i
n
Qki
 
hfUi; ^(1)k (t0)g

  G^k(t; Ui)
o2 I(Ui  u)
K^(Ui)
)
,
G^ki(t; u) =
1
nS^(u)
 nX
i=1
iQki
 
hfUi; ^(1)k (t0)g
I(Ui  u)
K^(Ui)

:
Eq.(4.7), along with an inverse-probability-weighted kernel density estimator of fk, can then
be used in Eq.(4.6) to estimate the variance of ^
(1)
k (t0).
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4.3.2 Estimating Equation Based Approach
An alternative method of estimating the MERL function at time t0 would be to directly
solve an appropriate estimating equation of the form
nX
i=1
 i(k(t0)) = 0; (4.8)
where  i() =
iQki
K(Ui)
[I(Ui > t0 + )   12I(Ui > t0]. Note that K() is unknown and hence it
must be estimate by some consistent method. Since this equation is not linear in , we can
use numerical methods such as the Secant method or Newton-Raphson method to solve the
equation for . We used the Secant method for this purpose to avoid computing numerical
derivative in the Newton-Raphson method. The solution to Eq.(4.8) will be referred to as
^
(2)
k (t0).
To estimate the variance, we will use the so-called sandwich estimator. (4.8). Explicitly,
var(^
(2)
k (t0)) =

1
n

B(^
(2)
k (t0))
A(^
(2)
k (t0))
2
;
where A() = S^ 0k(t0 + ) and B() =
nPn
i=1
iQki
K^(Ui)
o 1Pn
i=1f i()g2.
4.4 SIMULATION STUDY
We conducted a simulation study to evaluate the proposed methods. Since initial treatment
A1 and A2 are assigned by randomization, we only designed simulation studies for the in-
duction treatment A1. We generate n independent sets of observations described as follows.
Indicator of patient's response R was generated from a Bernoulli (R) distribution, where
R was varied between 0:1 and 0:7. For responders (R = 1), the B1 treatment assignment
indicator Z1 was generated from Bernoulli (1) distribution. We then dened Z2 = 1  Z1.
For non-responders (R = 0), we generated survival time TNR from exponential distribu-
tion with mean  = 0:5. For responders, a response time Ta was generated from exponential
( = 0:1). Patients receiving maintenance treatment Bk, post remission survival time T

k was
generated from three-parameter Weibull distribution as T k = (
1

)( exp( k)log(1   u))(
1

)
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, k = 1; 2. Following Jeong et al. [2008], the parameter values for  and  are set to 0:2
and 2, respectively, and 1 = 0:6 and 2 = 0:9. Therefore, the survival time for the i
th
patient, Ti = (1   Ri)TNRi + RifTai + Z1iT 1i + Z2iT 2ig. The censoring time Ci was taken
from a uniform distribution between 0 and C to reect about 30% of censoring and assumed
independent of all other variables. The observed survival Ui is min(Ti; Ci) and the complete
case indicator i is I(Ti < Ci).
Under dierent simulation scenarios obtained under dierent combination of parameters,
we generated 1000 samples of size n (200 and 500) and then estimated median residual
lifetime at 183 and 365 days.
In Table 4 and Table 5, we summarize estimators of the median residual lifetimes (Esti-
mates) and standard error (S.E.) for these estimators, along with 95% coverage probability
of estimates (CP). Table 4 gives the results from scenarios where patients were assigned to
the maintenance treatment with equal allocation. As can be seen, estimates and coverage
probabilities were similar for the SFB and EEB. For the SFB and EEB estimators, the
coverage probabilities in most cases achieved by the nominal level. These estimators were
approximately unbiased as shown by the small observed biases. Standard errors for the EEB
estimators were larger than the SFB estimators.
The cases with unequal probability of assignment to maintenance treatment are shown
in Table 5. Here 30% of the responders were assigned to B1 while 70% to B2. Performance of
the estimators, coverage probabilities and standard errors remain similar to the case where
the randomization was done with equal probability in Table 5. In this scenario, estimators
corresponding to the maintenance treatment with higher probability of randomization had
smaller standard errors compared to the strategy which shared the other maintenance treat-
ment. Specically, standard errors for A1B1 was larger than that for A1B2 with 30% of
responders being assigned to B1. This is expected since this form of randomization increases
the eective sample size of strategy A1B2 and reduces the number of patients followed in the
strategy A1B1.
In both Tables 4 and 5, both estimators gained eciency with increasing sample size.
Standard errors of the estimators and Monte Carlo standard errors were close to each other,
implying consistency of variance estimators for both methods.
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Overall, the estimator from SFB method has smaller standard errors than the EEB
estimator, and EEB estimator shows higher coverage rate than the SFB estimator.
4.5 ANALYSIS OF LEUKEMIA CALGB 8923 TRIAL
In this section, we apply the methods described in previous sections to estimate the me-
dian residual life time of patients treated with various treatment strategies. The data is
collected from a two-stage randomized clinical trial conducted by the Cancer and Leukemia
Group B (CALGB). This is a double-blinded placebo-controlled trial designed to examine
the eects of infusions of granulocyte-macrophage colony-stimulating factor (GM-CSF) fol-
lowing induction chemotherapy in acute myelogenous leukemia (AML) patients. Patients
are initially randomized to GM-SCF (n =193) or placebo (n=195) following treatment with
standard chemotherapy. Patients who achieved remission and consented to second stage
treatment (79 out of 193 in GM-CSF and 90 out of 195 in the placebo group) were re-
randomized into one of the intensication therapies: cytarabine (intensication I) and cy-
tarabine+mitoxantrone (Intensication II). In this process, 37 patients were assigned to
intensication I in the GM-CSF group whereas 45 were assigned to the same intensica-
tion in the placebo group. The remaining patients in each group received intensication
II. Therefore, there are 4 possible treatment strategies in this trial, namely, GM-CSF/I,
GM-CSF/II, Placebo/I, and Placebo/II, where for example, \GM-CSF/I" stands for \add
GM-CSF by infusion after chemotherapy followed by maintenance cytarabine, if respond to
chemotherapy with GM-CSF infusion".
In Table 6, we presented the estimators of the median residual lifetime at specic time
points for the treatment strategies, GM-CSF/I, GM-CSF/II, Placebo/I and Placebo/II, us-
ing the SFB [Eq. (4.4)] and EEB [Eq. (4.8)] methods. The median residual lifetimes at
three dierent time points of 150, 250, and 350 days were estimated. From the results pre-
sented in Table 6, the estimates under both methods SFB and EEB were similar to each
other, although the standard errors of the EEB estimates were larger compared to the SFB
estimates. Estimated MERL was smallest for strategy GM-CSF/I whereas it was largest for
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Table 4: Simulation results of estimation of MERL at two time points with Z = 0:5
n R t0 Method Strategy (t0) Estimates S.E. MC S.E. C.P.
200
0.4
183
SFB
A1B1 267.5 267:9 48:81 51:63 0:92
A1B2 235.2 235:2 44:59 47:31 0:92
EEB
A1B1 267.5 277:9 58:59 53:50 0:96
A1B2 235.2 242:3 49:96 48:17 0:96
365
SFB
A1B1 232.6 229:5 62:83 64:15 0:91
A1B2 193.8 190:0 53:42 57:73 0:91
EEB
A1B1 232.6 253:0 80:37 66:98 0:96
A1B2 193.8 209:7 63:10 62:85 0:96
0.7
183
SFB
A1B1 341.9 332:3 51:25 51:68 0:93
A1B2 285.6 283:6 47:58 44:42 0:94
EEB
A1B1 341.9 340:7 61:29 52:47 0:95
A1B2 285.6 289:8 52:33 44:52 0:98
365
SFB
A1B1 262.9 253:7 56:70 55:26 0:93
A1B2 209.5 205:1 48:63 48:33 0:93
EEB
A1B1 262.9 270:0 69:62 57:97 0:97
A1B2 209.5 214:9 54:11 49:47 0:96
500
0.4
183
SFB
A1B1 267.5 269:6 31:48 34:33 0:92
A1B2 235.2 233:0 28:66 29:82 0:94
EEB
A1B1 267.5 272:6 37:59 34:92 0:96
A1B2 235.2 235:4 31:51 30:18 0:96
365
SFB
A1B1 232.6 235:7 39:66 40:90 0:93
A1B2 193.8 193:1 33:91 34:99 0:93
EEB
A1B1 232.6 241:2 48:20 41:58 0:96
A1B2 193.8 197:7 37:49 35:31 0:96
0.7
183
SFB
A1B1 341.9 337:9 32:81 33:63 0:92
A1B2 285.6 282:6 30:02 28:70 0:95
EEB
A1B1 341.9 341:1 39:89 34:09 0:96
A1B2 285.6 284:6 32:97 28:61 0:97
365
SFB
A1B1 262.9 256:2 57:37 56:22 0:93
A1B2 209.5 206:8 49:33 46:65 0:95
EEB
A1B1 262.9 271:7 69:58 58:27 0:97
A1B2 209.5 218:2 54:97 48:53 0:98
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Table 5: Simulation results of estimation of MERL at two time points with Z = 0:3
N R t0 Method Strategy (t0) Estimates S.E. MC S.E. C.P.
200
0.4
183
SFB
A1B1 273.9 265:3 61:47 66:04 0:88
A1B2 239.9 235:5 37:56 39:23 0:93
EEB
A1B1 273.9 280:4 71:66 87:88 0:93
A1B2 239.9 240:7 42:80 38:93 0:96
365
SFB
A1B1 234.3 227:1 82:50 80:26 0:90
A1B2 193.4 189:6 44:68 46:31 0:91
EEB
A1B1 234.3 262:0 105:79 85:32 0:95
A1B2 193.4 201:5 51:76 49:13 0:96
0.7
183
SFB
A1B1 343.5 331:1 67:15 67:59 0:91
A1B2 285.1 284:6 38:79 36:89 0:96
EEB
A1B1 343.5 344:8 77:48 65:53 0:94
A1B2 285.1 289:3 43:81 37:28 0:97
365
SFB
A1B1 262.1 252:3 76:80 74:32 0:90
A1B2 210.4 206:5 40:55 38:73 0:95
EEB
A1B1 262.1 278:9 93:83 77:28 0:95
A1B2 210.4 214:0 46:30 39:53 0:97
500
0.4
183
SFB
A1B1 273.9 270:8 40:19 42:62 0:92
A1B2 239.9 235:8 24:34 25:34 0:93
EEB
A1B1 273.9 275:4 46:67 43:25 0:95
A1B2 239.9 237:4 27:45 25:25 0:96
365
SFB
A1B1 234.3 234:1 52:10 53:73 0:93
A1B2 193.4 193:7 28:47 29:14 0:95
EEB
A1B1 234.3 244:9 62:80 57:57 0:95
A1B2 193.4 196:9 32:27 29:67 0:97
0.7
183
SFB
A1B1 343.5 339:1 43:15 45:37 0:92
A1B2 285.1 282:2 24:37 23:63 0:95
EEB
A1B1 343.5 344:3 50:15 45:55 0:95
A1B2 285.1 283:9 27:44 23:69 0:97
365
SFB
A1B1 262.1 258:9 49:04 48:26 0:92
A1B2 210.4 207:6 25:54 25:31 0:93
EEB
A1B1 262.1 268:5 58:73 52:75 0:96
A1B2 210.4 209:7 28:80 25:19 0:96
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Table 6: Estimated median residual lifetime for CALGB 8923 data at dierent days
Strategy t0 (days)
Methods
SFB EEB
GM-CSF/I
150 290:0 (21:07) 309:2 (47:11)
250 260:0 (23:93) 275:5 (52:30)
350 233:0 (26:92) 246:4 (54:40)
GM-CSF/II
150 288:0 (21:66) 281:8 (45:08)
250 233:0 (22:80) 239:8 (50:20)
350 192:0 (27:08) 235:4 (66:27)
Placebo/I
150 313:0 (27:08) 318:0 (52:10)
250 285:0 (27:59) 303:1 (59:51)
350 271:0 (31:55) 271:2 (64:28)
Placebo/II
150 401:0 (45:47) 409:6 (106:80)
250 395:0 (47:62) 459:2 (153:03)
350 500:0 (68:60) 496:4 (230:50)
the strategy Placebo/II at all three time points. When the time of interest increased, median
residual lifetimes decreased, except for the strategy \do not give GM-CSF after chemother-
apy, and when a response is observed treat with second maintenance". The estimates of the
median residual lifetimes over time are presented in Figure 3 for all four treatment strategies.
It shows the evolution of the median residual lifetime over the duration of the trial.
For all strategies, the median residual lifetimes initially increased, most likely due to
the eect of initial treatment. After about 50 days, the median residual lifetimes began
to decrease for the strategies GM-CSF/I, GM-CSF/II and Placebo/I. Placebo/II shows the
increasing median residual lifetimes throughout which may be due to the fact that some of
the patients survived extremely long under this strategy. This result has been consistent
with the ndings from previous studies based on mean survival or survival curve (Lunceford
et al. [2002]; Wahed and Tsiatis [2004]) where it has been showed that the infusion with
GM-CSF was not benecial to patients in terms of overall survival.
40
0   100 200 300 400
0
100
200
300
400
500
600
700
                                                                                                                                                              Days
−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
GM−CSF/I  151                              86                             68                            56                            43     Patients                
GM−CSF/II 156                              91                             72                            59                            43                          
Placebo/I    150                              97                             78                            66                            51                       
Placebo/II   150                              97                             73                            62                            49                        
Me
dia
n r
es
idu
al 
life
tim
es
 
 
GM−CSF/I
GM−CSF/II
Placebo/I
Placebo/II
Figure 3: Survival function based median residual lifetimes for CALGB 8923 data with
number of the patients at risk for each strategy
4.6 DISCUSSION
In this chapter, two methods were proposed to estimate the median residual life function for
sequentially randomized trials. First, we estimated the median residual lifetime indirectly
from the estimated survival curve. The survival curve estimation was done based on the
inverse-probability-weighting. One important limitation of this estimator is that we need
to estimate the density function to estimate the variance. In addition to SFB method, the
median residual lifetime can also be estimated by directly solving the estimating equation
of the median residual lifetime.
As can be seen from our simulation study, the SFB and EEB estimators are approximately
unbiased. The estimator from SFB method has smaller standard errors than the EEB
estimator which leads to higher coverage rates for the latter. Future research in this area
might consider including covariates in the estimation process. Other important research
might include developing test statistics to compare MERL across dierent strategies.
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5.0 CONCLUSION
We rst have compared up-front and sequential randomization designs as prospective de-
signs for comparing dynamic treatment strategies. Most previous studies investigated these
methods but few compared them with respect to eciency. Our simulation results indicated
that the sequential randomization provides better estimator for ATS's compared to up-front
randomization designs. Specically, sequential randomization is better than up-front ran-
domization in terms of eciency of the estimators and the power of statistical hypothesis
testing. In the latter half of the study, we proposed nonparametric estimation methods
to estimate the MERL function for SRT. One estimator for MERL function was obtained
by using probability-adjusted estimator (Lunceford et al. [2002]). The other estimator was
obtained by directly solving the estimating equation. We demonstrated our methods by
applying to a Leukemia clinical trial data set. Our simulation study shows that SFB and
EEB estimators for SRT are approximately unbiased in large samples.
One advantage of the SFB methods is that it can be calculated directly from the survival
curve estimator. One limitation of this approach is that it requires density estimation for
the purpose of estimating its variance. On the other hand, EEB estimator although less
ecient, does not require any such limitation.
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APPENDIX
PROGRAMS WRITTEN IN MATLAB c
A.1 UP-FRONT AND SEQUENTIAL RANDOMIZATION IN CLINICAL
TRIALS
clear all;
% =========================================================
% Function to find nearest value
% =========================================================
function K = fOne(U,tk,Ku);
n = length(U);
for i=1:n
index = find(U(i)==tk);
if length(index)==0
[val1 index] = min(abs(U(i)-tk));
end
K(i) = Ku(index(1));
end
% =========================================================
% Function to find Kaplan Meier Estimator
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% =========================================================
function [K S] = kmest(U,D)
D1 = 1-D;
n = length(D);
[K,x] = ecdf(U,'censoring',D,'function','survivor');
[S,x1] = ecdf(U,'censoring',D1,'function','survivor');
K = fOne(U,x,K);
S = fOne(U,x1,S);
for j = 2:n
if K(j) == 0 K(j) = K(j-1); end
if S(j) == 0 S(j) = S(j-1); end
end
K = K';
S = S';
% =========================================================
% Function to find Density function
% =========================================================
function [Den1_R0 Den1_t0_R0] = denS(U_R0, Q, D1_R0, t0)
n_R0 = length(U_R0);
[den1_R0,x1] = ksdensity(U_R0,'weights',Q,'censoring',D1_R0,
'npoints',n_R0);
Den1_R0 = fOne(U_R0,x1,den1_R0);
Den1_t0_R0 = fOne(t0,U_R0,Den1_R0);
function f = secfunc1(p1)
load FileforSecant
f = (sum((D./K.*Q1.*((U>t0+p1)-0.5.*(U>t0))))/sum(D./K.*Q1));
% =========================================================
% Function to call secant function
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% =========================================================
function f = secfunc1(p1)
load FileforSecant
f = (sum((D./K.*Q1.*((U>t0+p1)-0.5.*(U>t0))))/sum(D./K.*Q1));
% =========================================================
% Function to find Inverse Survival
% =========================================================
function [S_half1_pmb Sinv1_pmb Sinv1_pmb_t0 S_half1_pmb_t0] =
S_find(S1pmb, U_pmb, t0)
S_half1_pmb = 0.5*S1pmb;
Sinv1_pmb = fOne(S_half1_pmb,S1pmb,U_pmb);
Sinv1_pmb_t0 = fOne(t0,U_pmb,Sinv1_pmb);
S_half1_pmb_t0 = fOne(t0,U_pmb,S_half1_pmb);
% =========================================================
% Function to calculate Coverage Probabilities
% =========================================================
function [Var331 Var332 Se331 Se332 Cp331 Cp332]
= CP1(Den31_t0, Den32_t0, D, K, Q1, Q2, U, t0, Theta31, Theta32,
mu31, mu32)
n = length(U);
AA31 = Den31_t0^2;
AA32 = Den32_t0^2;
BB31 = sum(((D./K.*Q1.*((U>t0+Theta31)-0.5.*(U>t0)))).^2)/n;
BB32 = sum(((D./K.*Q2.*((U>t0+Theta32)-0.5.*(U>t0)))).^2)/n;
Var331 = (BB31/AA31)/n;
Var332 = (BB32/AA32)/n;
Se331 = sqrt(Var331);
Se332 = sqrt(Var332);
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CL_L331 = Theta31 -1.96* Se331;
CL_U331 = Theta31 + 1.96*Se331;
CL_L332 = Theta32 -1.96* Se332;
CL_U332 = Theta32 + 1.96*Se332;
Cp331 = (mu31 >= CL_L331) * (CL_U331 >= mu31);
Cp332 = (mu32 >= CL_L332) * (CL_U332 >= mu32);
% =========================================================
% Begin Main codes
% =========================================================
clear all;
nos = 100; % iterations
nT = 200; % sample size
%%make effect size small like 0.25? 0.1
piA = 0.5; %for Treatment A
piR1 = 0.5; %response for A1
piR2 = 0.5; %response for A2
piB = 0.5; %proportion for B
piC = 0.5; %proportion for C
%%%%%% same true mean
% m11d = 15;
% m1d1 = 15;
% m12d = 15;
% m1d2 = 15;
% m21d = 15;
% m2d1 = 15;
% m22d = 15;
% m2d2 = 15;
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%%%%% different true mean
m11d = 15;
m1d1 = 20;
m12d = 22;
m1d2 = 15;
m21d = 15;
m2d1 = 20;
m22d = 22;
m2d2 = 15;
n1 = piA*nT; % # of people in A1
n2 = (1-piA)*nT; % # of people in A2
v1 = 6;
v2 = 8;
for k = 1:nos
U01 = rand(n1,1);
U02 = rand(n2,1);
U1 = rand(n1,1);
U2 = rand(n1,1);
V1 = rand(n1,1);
V2 = rand(n1,1);
V21 = rand(n2,1);
V22 = rand(n2,1);
U21 = rand(n2,1);
U22 = rand(n2,1);
% ====================================================================
% For A1
% ====================================================================
for i = 1:n1
%indicator for receiving second treatment
if V1(i) < piR1 R1(i) = 1;
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else R1(i) = 0;
end
%indicator for second treatment method ( responders piB
%non-responders piC )
if U1(i) < piB Z1(i) = 1;
else Z1(i) = 0;
end
if U2(i) < piC Z3(i) = 1;
else Z3(i) = 0;
end
%indicator for 4 groups in URT
if U01(i) < 0.25 X1(i) = 1;
else X1(i) = 0;
end
if (0.25 <= U01(i)) && (U01(i)< 0.5) X2(i) = 1;
else X2(i) = 0;
end
if (0.5 <= U01(i)) && (U01(i) < 0.75) X3(i) = 1;
else X3(i) = 0;
end
if U01(i) >= 0.75 X4(i) = 1;
else X4(i) = 0;
end
%distribution of observed data
y11d = randn(n1,1)*v1 + m11d;
y1d1 = randn(n1,1)*v2 + m1d1;
y12d = randn(n1,1)*v1 + m12d;
y1d2 = randn(n1,1)*v2 + m1d2;
%split data into 4 different groups in URT
y111(i) = (R1(i)*y11d(i) + (1-R1(i))*y1d1(i))*X1(i);
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y112(i) = (R1(i)*y11d(i) + (1-R1(i))*y1d2(i))*X2(i);
y121(i) = (R1(i)*y12d(i) + (1-R1(i))*y1d1(i))*X3(i);
y122(i) = (R1(i)*y12d(i) + (1-R1(i))*y1d2(i))*X4(i);
%total observed data in SRT with counterfactuals
y_tot(i) = R1(i)*(Z1(i)*y11d(i) + (1-Z1(i))*y12d(i)) +
(1-R1(i))*(Z3(i)*y1d1(i) + (1-Z3(i))*y1d2(i));
%divide into 4 groups based on second treatment agreement and
%treatment method in SRT
W111(i) = (((R1(i)*Z1(i))/piB) + ((((1-R1(i))*Z3(i)))/piC)); % IPW
W112(i) = (((R1(i)*Z1(i))/piB) + ((((1-R1(i))*(1-Z3(i))))/(1-piC)));
W121(i) = (((R1(i)*(1-Z1(i)))/(1-piB)) + ((((1-R1(i))*Z3(i)))/piC));
W122(i) = (((R1(i)*(1-Z1(i)))/(1-piB)) +
((((1-R1(i))*(1-Z3(i))))/(1-piC)));
y1_2(i) = (((R1(i)*Z1(i))/piB) + ((((1-R1(i))*Z3(i)))/piC))
*y_tot(i);
y2_2(i) = (((R1(i)*Z1(i))/piB) + ((((1-R1(i))*(1-Z3(i))))/(1-piC)))
*y_tot(i);
y3_2(i) = (((R1(i)*(1-Z1(i)))/(1-piB)) + ((((1-R1(i))*Z3(i)))/piC))
*y_tot(i);
y4_2(i) = (((R1(i)*(1-Z1(i)))/(1-piB)) +
(((1-R1(i))*(1-Z3(i))))/(1-piC)))*y_tot(i);
end
% ======================================================================
% For A2
% ======================================================================
for i = 1:n2
%indicator for receiving second treatment
if V22(i) < piR2 R2(i) = 1;
else R2(i) = 0;
end
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%indicator for second treatment method
if U21(i) < piB Z2(i) = 1;
else Z2(i) = 0;
end
if U22(i) < piC Z4(i) = 1;
else Z4(i) = 0;
end
%indicator for 4 groups in design 1
if U02(i) < 0.25 X1(i) = 1;
else X1(i) = 0;
end
if (0.25 <= U02(i)) && (U02(i)< 0.5) X2(i) = 1;
else X2(i) = 0;
end
if (0.5 <= U02(i)) && (U02(i) < 0.75) X3(i) = 1;
else X3(i) = 0;
end
if U02(i) >= 0.75 X4(i) = 1;
else X4(i) = 0;
end
%distribution of observed data
y21d = randn(n2,1)*v1 + m21d;
y2d1 = randn(n2,1)*v2 + m2d1;
y22d = randn(n2,1)*v1 + m22d;
y2d2 = randn(n2,1)*v2 + m2d2;
%split data into 4 different groups in URT for rest of R
y211(i) = ((R2(i))*y21d(i) + (1-R2(i))*y2d1(i))*X1(i);
y212(i) = ((R2(i))*y21d(i) + (1-R2(i))*y2d2(i))*X2(i);
y221(i) = ((R2(i))*y22d(i) + (1-R2(i))*y2d1(i))*X3(i);
y222(i) = ((R2(i))*y22d(i) + (1-R2(i))*y2d2(i))*X4(i);
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%total observed data in SRT with counterfactuals
y_tot_2a(i) = (R2(i))*(Z2(i)*y21d(i) + (1-Z2(i))*y22d(i)) +
(1-R2(i))*(Z4(i)*y2d1(i) + (1-Z4(i))*y2d2(i));
%divide into 4 groups based on second treatment agreement and
%treatment method in SRT
W211(i) = ((((R2(i))*Z2(i))/piB) + ((((1-R2(i))*Z4(i)))/piC));
% IPW
W212(i) = ((((R2(i))*Z2(i))/piB) + ((((1-R2(i))*
(1-Z4(i))))/(1-piC)));
W221(i) = ((((R2(i))*(1-Z2(i)))/(1-piB)) +
((((1-R2(i))*Z4(i)))/piC));
W222(i) = ((((R2(i))*(1-Z2(i)))/(1-piB)) +
((((1-R2(i))*(1-Z4(i))))/(1-piC)));
y1_2_2a(i) = ((((R2(i))*Z2(i))/piB) + ((((1-R2(i))*Z4(i)))/piC))
*y_tot_2a(i);
y2_2_2a(i) = ((((R2(i))*Z2(i))/piB) +
((((1-R2(i))*(1-Z4(i))))/(1-piC)))*y_tot_2a(i);
y3_2_2a(i) = ((((R2(i))*(1-Z2(i)))/(1-piB)) +
((((1-R2(i))*Z4(i)))/piC))*y_tot_2a(i);
y4_2_2a(i) = ((((R2(i))*(1-Z2(i)))/(1-piB)) +
((((1-R2(i))*(1-Z4(i))))/(1-piC)))*y_tot_2a(i);
end
%%remove all zeros from each outcome vector in SRT
index111 = find(y111);y1_n1 = y111(index111);
index112 = find(y112);y2_n1 = y112(index112);
index121 = find(y121);y3_n1 = y121(index121);
index122 = find(y122);y4_n1 = y122(index122);
index211 = find(y211);y1_n1_2a = y211(index211);
index212 = find(y212);y2_n1_2a = y212(index212);
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index221 = find(y221);y3_n1_2a = y221(index221);
index222 = find(y222);y4_n1_2a = y222(index222);
%%counting elements after removing zeros
size1 = length(y1_n1);
size2 = length(y2_n1);
size3 = length(y3_n1);
size4 = length(y4_n1);
size1_2a = length(y1_n1_2a);
size2_2a = length(y2_n1_2a);
size3_2a = length(y3_n1_2a);
size4_2a = length(y4_n1_2a);
% ======================================================================
% estimate means
% ======================================================================
%% mean from URT
m111(k) = mean(y1_n1);
m112(k) = mean(y2_n1);
m121(k) = mean(y3_n1);
m122(k) = mean(y4_n1);
m211(k) = mean(y1_n1_2a);
m212(k) = mean(y2_n1_2a);
m221(k) = mean(y3_n1_2a);
m222(k) = mean(y4_n1_2a);
%% mean in SRT
nmu111(k) = mean(y1_2);
nmu112(k) = mean(y2_2);
nmu121(k) = mean(y3_2);
nmu122(k) = mean(y4_2);
nmu211(k) = mean(y1_2_2a);
nmu212(k) = mean(y2_2_2a);
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nmu221(k) = mean(y3_2_2a);
nmu222(k) = mean(y4_2_2a);
%% mean in SRT probability adjusted
mu111(k) = sum(y1_2)/sum(W111);
mu112(k) = sum(y2_2)/sum(W112);
mu121(k) = sum(y3_2)/sum(W121);
mu122(k) = sum(y4_2)/sum(W122);
mu211(k) = sum(y1_2_2a)/sum(W211);
mu212(k) = sum(y2_2_2a)/sum(W212);
mu221(k) = sum(y3_2_2a)/sum(W221);
mu222(k) = sum(y4_2_2a)/sum(W222);
% ==================================================================
% variance for estimators
% ==================================================================
%% sample variance for URT
s111_1(k) = (sum((y1_n1 - m111(k)).^2)/(size1-1));
s112_1(k) = (sum((y2_n1 - m112(k)).^2)/(size2-1));
s121_1(k) = (sum((y3_n1 - m121(k)).^2)/(size3-1));
s122_1(k) = (sum((y4_n1 - m122(k)).^2)/(size4-1));
s111_1_2a(k) = (sum((y1_n1_2a - m211(k)).^2)/(size1_2a-1));
s112_1_2a(k) = (sum((y2_n1_2a - m212(k)).^2)/(size2_2a-1));
s121_1_2a(k) = (sum((y3_n1_2a - m221(k)).^2)/(size3_2a-1));
s122_1_2a(k) = (sum((y4_n1_2a - m222(k)).^2)/(size4_2a-1));
%% M-est for var. in SRT
B111(k) = (sum((W111.*y_tot-nmu111(k)).^2)/n1^2);
B112(k) = (sum((W112.*y_tot-nmu112(k)).^2)/n1^2);
B121(k) = (sum((W121.*y_tot-nmu121(k)).^2)/n1^2);
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B122(k) = (sum((W122.*y_tot-nmu122(k)).^2)/n1^2);
B211(k) = (sum((W211.*y_tot_2a-nmu211(k)).^2)/n2^2);
B212(k) = (sum((W212.*y_tot_2a-nmu212(k)).^2)/n2^2);
B221(k) = (sum((W221.*y_tot_2a-nmu221(k)).^2)/n2^2);
B222(k) = (sum((W222.*y_tot_2a-nmu222(k)).^2)/n2^2);
%% covariance for SRT
C12_2(k) = sum((W111.*y_tot-nmu111(k)).*(W112.*y_tot-nmu112(k)))/(n1^2);
C13_2(k) = sum((W111.*y_tot-nmu111(k)).*(W121.*y_tot-nmu121(k)))/(n1^2);
C14_2(k) = sum((W111.*y_tot-nmu111(k)).*(W122.*y_tot-nmu122(k)))/(n1^2);
C23_2(k) = sum((W112.*y_tot-nmu112(k)).*(W121.*y_tot-nmu121(k)))/(n1^2);
C24_2(k) = sum((W112.*y_tot-nmu112(k)).*(W122.*y_tot-nmu122(k)))/(n1^2);
C34_2(k) = sum((W121.*y_tot-nmu121(k)).*(W122.*y_tot-nmu122(k)))/(n1^2);
C12_2_2a(k) = sum((W211.*y_tot_2a-nmu211(k)).*
(W212.*y_tot_2a-nmu212(k)))/(n2^2);
C13_2_2a(k) = sum((W211.*y_tot_2a-nmu211(k)).*
(W221.*y_tot_2a-nmu221(k)))/(n2^2);
C14_2_2a(k) = sum((W211.*y_tot_2a-nmu211(k)).*
(W222.*y_tot_2a-nmu222(k)))/(n2^2);
C23_2_2a(k) = sum((W212.*y_tot_2a-nmu212(k)).*
(W221.*y_tot_2a-nmu221(k)))/(n2^2);
C24_2_2a(k) = sum((W212.*y_tot_2a-nmu212(k)).*
(W222.*y_tot_2a-nmu222(k)))/(n2^2);
C34_2_2a(k) = sum((W221.*y_tot_2a-nmu221(k)).*
(W222.*y_tot_2a-nmu222(k)))/(n2^2);
%% M-est for var. in SRTPA
BM111(k) = (sum((W111.*(y_tot-mu111(k))).^2)/(n1*sum(W111)^2));
BM112(k) = (sum((W112.*(y_tot-mu112(k))).^2)/(n1*sum(W112)^2));
BM121(k) = (sum((W121.*(y_tot-mu121(k))).^2)/(n1*sum(W121)^2));
BM122(k) = (sum((W122.*(y_tot-mu122(k))).^2)/(n1*sum(W122)));
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BM211(k) = (sum((W211.*(y_tot_2a-mu211(k))).^2)/(n2*sum(W211)^2));
BM212(k) = (sum((W212.*(y_tot_2a-mu212(k))).^2)/(n2*sum(W212)^2));
BM221(k) = (sum((W221.*(y_tot_2a-mu221(k))).^2)/(n2*sum(W221)^2));
BM222(k) = (sum((W222.*(y_tot_2a-mu222(k))).^2)/(n2*sum(W222)^2));
%% covariance for SRTPA
C12_3(k) = sum((W111.*(y_tot-mu111(k))).*(W112.*(y_tot-mu112(k))))
/(n1^2);
C13_3(k) = sum((W111.*(y_tot-mu111(k))).*(W121.*(y_tot-mu121(k))))
/(n1^2);
C14_3(k) = sum((W111.*(y_tot-mu111(k))).*(W122.*(y_tot-mu122(k))))
/(n1^2);
C23_3(k) = sum((W112.*(y_tot-mu112(k))).*(W121.*(y_tot-mu121(k))))
/(n1^2);
C24_3(k) = sum((W112.*(y_tot-mu112(k))).*(W122.*(y_tot-mu122(k))))
/(n1^2);
C34_3(k) = sum((W121.*(y_tot-mu121(k))).*(W122.*(y_tot-mu122(k))))
/(n1^2);
C12_3_2a(k) = sum((W211.*(y_tot_2a-mu211(k))).*
(W212.*(y_tot_2a-mu212(k))))/(n2^2);
C13_3_2a(k) = sum((W211.*(y_tot_2a-mu211(k))).*
(W221.*(y_tot_2a-mu221(k))))/(n2^2);
C14_3_2a(k) = sum((W211.*(y_tot_2a-mu211(k))).*
(W222.*(y_tot_2a-mu222(k))))/(n2^2);
C23_3_2a(k) = sum((W212.*(y_tot_2a-mu212(k))).*
(W221.*(y_tot_2a-mu221(k))))/(n2^2);
C24_3_2a(k) = sum((W212.*(y_tot_2a-mu212(k))).*
(W222.*(y_tot_2a-mu222(k))))/(n2^2);
C34_3_2a(k) = sum((W221.*(y_tot_2a-mu221(k))).*
(W222.*(y_tot_2a-mu222(k))))/(n2^2);
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%% to test 8 strategies
new_contrast = [1 0 -1 0 0 0 0 0 ;0 1 0 -1 0 0 0 0 ; ...
1 -1 0 0 0 0 0 0 ;0 0 0 0 1 0 -1 0;0 0 0 0 0 1 0 -1;
0 0 0 0 1 -1 0 0];
%% testing in URT
new_mean1 = [m111(k) m112(k) m121(k) m122(k) m211(k) m212(k)
m221(k) m222(k)];
%% var-cov matrix for URT
new_cov1 = [s111_1(k)/size1 0 0 0 0 0 0 0;
0 s112_1(k)/size2 0 0 0 0 0 0;...
0 0 s121_1(k)/size3 0 0 0 0 0; 0 0 0 s122_1(k)/size4 0 0 0 0;...
0 0 0 0 s111_1_2a(k)/size1_2a 0 0 0;
0 0 0 0 0 s112_1_2a(k)/size2_2a 0 0;...
0 0 0 0 0 0 s121_1_2a(k)/size3_2a 0;
0 0 0 0 0 0 0 s122_1_2a(k)/size4_2a];
ts_tot_1(k) = new_mean1*new_contrast'*
inv(new_contrast*new_cov1*new_contrast')*new_contrast*new_mean1';
%% testing in SRTPA
new_mean = [mu111(k) mu112(k) mu121(k) mu122(k) mu211(k)
mu212(k) mu221(k) mu222(k)];
new_cov = [BM111(k) C12_3(k) C13_3(k) C14_3(k) 0 0 0 0 ;
C12_3(k) BM112(k) C23_3(k) C24_3(k) 0 0 0 0;...
C13_3(k) C23_3(k) BM121(k) C34_3(k) 0 0 0 0;
C14_3(k) C24_3(k) C34_3(k) BM122(k) 0 0 0 0 ;...
0 0 0 0 BM211(k) C12_3_2a(k) C13_3_2a(k) C14_3_2a(k);
0 0 0 0 C12_3_2a(k) BM212(k) C23_3_2a(k) C24_3_2a(k);...
0 0 0 0 C13_3_2a(k) C23_3_2a(k) BM221(k) C34_3_2a(k);
0 0 0 0 C14_3_2a(k) C24_3_2a(k) C34_3_2a(k) BM222(k)];
ts_tot_3(k) = new_mean*new_contrast'*
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inv(new_contrast*new_cov*new_contrast')*new_contrast*new_mean';
%% A1, A2 testing
%% mean matrices
mean_1 = [m111(k) m112(k) m121(k) m122(k)]; % URT A1
mean_2 = [nmu111(k) nmu112(k) nmu121(k) nmu122(k)]; % SRT A1
mean_3 = [mu111(k) mu112(k) mu121(k) mu122(k)]; % SRTPA A1
mean_1_2a = [m211(k) m212(k) m221(k) m222(k)]; %URT A2
mean_2_2a = [nmu211(k) nmu212(k) nmu221(k) nmu222(k)]; %SRT A2
mean_3_2a = [mu211(k) mu212(k) mu221(k) mu222(k)]; %SRTPA A2
contrast = [1 0 -1 0;0 1 0 -1; 1 -1 0 0];
%% Var-Cov matrix for URT
v_cov_1 = [s111_1(k)/size1 0 0 0; 0 s112_1(k)/size2 0 0;...
0 0 s121_1(k)/size3 0; 0 0 0 s122_1(k)/size4];
v_cov_1_2a = [s111_1_2a(k)/size1_2a 0 0 0;
0 s112_1_2a(k)/size2_2a 0 0;...
0 0 s121_1_2a(k)/size3_2a 0; 0 0 0 s122_1_2a(k)/size4_2a];
%% Var-Cov matrix for SRT
v_cov_2 = [B111(k) C12_2(k) C13_2(k) C14_2(k);
C12_2(k) B112(k) C23_2(k) C24_2(k);...
C13_2(k) C23_2(k) B121(k) C34_2(k); C14_2(k) C24_2(k)
C34_2(k) B122(k)];
v_cov_2_2a = [B211(k) C12_2_2a(k) C13_2_2a(k) C14_2_2a(k);
C12_2_2a(k) B212(k) C23_2_2a(k) C24_2_2a(k);...
C13_2_2a(k) C23_2_2a(k) B221(k) C34_2_2a(k); C14_2_2a(k)
C24_2_2a(k) C34_2_2a(k) B222(k)];
%% Var-Cov matrix for SRTPA
v_cov_3 = [BM111(k) C12_3(k) C13_3(k) C14_3(k); C12_3(k)
BM112(k) C23_3(k) C24_3(k);...
C13_3(k) C23_3(k) BM121(k) C34_3(k); C14_3(k) C24_3(k)
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C34_3(k) BM122(k)];
v_cov_3_2a = [BM211(k) C12_3_2a(k) C13_3_2a(k) C14_3_2a(k);
C12_3_2a(k) BM212(k) C23_3_2a(k) C24_3_2a(k);...
C13_3_2a(k) C23_3_2a(k) BM221(k) C34_3_2a(k); C14_3_2a(k)
C24_3_2a(k) C34_3_2a(k) BM222(k)];
%% Test Statistics
%% URT A1
ts_1(k) = mean_1*contrast'*inv(contrast*v_cov_1*contrast')*
contrast*mean_1';
%% SRTPA A1
ts_3(k) = mean_3*contrast'*inv(contrast*v_cov_3*contrast')*
contrast*mean_3';
%% URT A2
ts_1_2a(k) =
mean_1_2a*contrast'*inv(contrast*v_cov_1_2a*contrast')*contrast*mean_1_2a';
%% SRTPA A2
ts_3_2a(k) =
mean_3_2a*contrast'*inv(contrast*v_cov_3_2a*contrast')*contrast*mean_3_2a';
% ========================================================================
% comparing test statistics with chi-sq critical values
% ========================================================================
%% for URT
if abs(ts_1(k)) >= 7.82
count1(k) = 1;
else count1(k) = 0;
end
if abs(ts_1_2a(k)) >= 7.82
count1_2a(k) = 1;
else count1_2a(k) = 0;
end
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if abs(ts_tot_1(k)) >= 14.02
count_tot_1(k) = 1;
else count_tot_1(k) = 0;
end
%% for SRTPA
if abs(ts_tot_3(k)) >= 14.02
count_tot_3(k) = 1;
else count_tot_3(k) = 0;
end
if abs(ts_3(k)) >= 7.82
count3(k) = 1;
else count3(k) = 0;
end
if abs(ts_3_2a(k)) >= 7.82
count3_2a(k) = 1;
else count3_2a(k) = 0;
end
end
%%=========================================================================
% Coverage probabilities
%%=========================================================================
%% true means for A1
t_mu111 = piR1*m11d + (1-piR1)*m1d1;
t_mu112 = piR1*m11d + (1-piR1)*m1d2;
t_mu121 = piR1*m12d + (1-piR1)*m1d1;
t_mu122 = piR1*m12d + (1-piR1)*m1d2;
%% true means for A2
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t_mu211 = piR2*m21d + (1-piR2)*m2d1;
t_mu212 = piR2*m21d + (1-piR2)*m2d2;
t_mu221 = piR2*m22d + (1-piR2)*m2d1;
t_mu222 = piR2*m22d + (1-piR2)*m2d2;
%% Confidence interval in URT
U_CL111 = m111 - 1.96*sqrt(s111_1/size1);
U_CU111 = m111 + 1.96*sqrt(s111_1/size1);
U_CL112 = m112 - 1.96*sqrt(s112_1/size2);
U_CU112 = m112 + 1.96*sqrt(s112_1/size2);
U_CL121 = m121 - 1.96*sqrt(s121_1/size3);
U_CU121 = m121 + 1.96*sqrt(s121_1/size3);
U_CL122 = m122 - 1.96*sqrt(s122_1/size4);
U_CU122 = m122 + 1.96*sqrt(s122_1/size4);
U_CL211 = m211 - 1.96*sqrt(s111_1_2a/size1_2a);
U_CU211 = m211 + 1.96*sqrt(s111_1_2a/size1_2a);
U_CL212 = m212 - 1.96*sqrt(s112_1_2a/size2_2a);
U_CU212 = m212 + 1.96*sqrt(s112_1_2a/size2_2a);
U_CL221 = m221 - 1.96*sqrt(s121_1_2a/size3_2a);
U_CU221 = m221 + 1.96*sqrt(s121_1_2a/size3_2a);
U_CL222 = m222 - 1.96*sqrt(s122_1_2a/size4_2a);
U_CU222 = m222 + 1.96*sqrt(s122_1_2a/size4_2a);
%% coverage probability in URT
U_CP111 = (t_mu111 >= U_CL111) .* (t_mu111 <= U_CU111);
U_CP112 = (t_mu112 >= U_CL112) .* (t_mu112 <= U_CU112);
U_CP121 = (t_mu121 >= U_CL121) .* (t_mu121 <= U_CU121);
U_CP122 = (t_mu122 >= U_CL122) .* (t_mu122 <= U_CU122);
U_CP211 = (t_mu211 >= U_CL211) .* (t_mu211 <= U_CU211);
U_CP212 = (t_mu212 >= U_CL212) .* (t_mu212 <= U_CU212);
U_CP221 = (t_mu221 >= U_CL221) .* (t_mu221 <= U_CU221);
U_CP222 = (t_mu222 >= U_CL222) .* (t_mu222 <= U_CU222);
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%% Confidence interval in SRTPA
CL111 = mu111 - 1.96*sqrt(BM111);
CU111 = mu111 + 1.96*sqrt(BM111);
CL112 = mu112 - 1.96*sqrt(BM112);
CU112 = mu112 + 1.96*sqrt(BM112);
CL121 = mu121 - 1.96*sqrt(BM121);
CU121 = mu121 + 1.96*sqrt(BM121);
CL122 = mu122 - 1.96*sqrt(BM122);
CU122 = mu122 + 1.96*sqrt(BM122);
CL211 = mu211 - 1.96*sqrt(BM211);
CU211 = mu211 + 1.96*sqrt(BM211);
CL212 = mu212 - 1.96*sqrt(BM212);
CU212 = mu212 + 1.96*sqrt(BM212);
CL221 = mu221 - 1.96*sqrt(BM221);
CU221 = mu221 + 1.96*sqrt(BM221);
CL222 = mu222 - 1.96*sqrt(BM222);
CU222 = mu222 + 1.96*sqrt(BM222);
%% coverage probability in SRTPA
CP111 = (t_mu111 >= CL111) .* (t_mu111 <= CU111);
CP112 = (t_mu112 >= CL112) .* (t_mu112 <= CU112);
CP121 = (t_mu121 >= CL121) .* (t_mu121 <= CU121);
CP122 = (t_mu122 >= CL122) .* (t_mu122 <= CU122);
CP211 = (t_mu211 >= CL211) .* (t_mu211 <= CU211);
CP212 = (t_mu212 >= CL212) .* (t_mu212 <= CU212);
CP221 = (t_mu221 >= CL221) .* (t_mu221 <= CU221);
CP222 = (t_mu222 >= CL222) .* (t_mu222 <= CU222);
% latex(P2,'%.3f')
% savefile1 = ['VC55' num2str(piR1*10) '51.mat'];
% save(savefile1, 'P*')
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% save savefile Policy*
% msave('VC5551.mat','P*');
% save VC55581.mat Policy*
% end
% end
% end
% diary vc_table_out11
PPi = [piA piR1 piR2 piB piC ];
PPower = [sum(count_tot_1)/nos sum(count_tot_3)/nos];
P1 = [ mean(m111') sqrt(mean(s111_1)/size1)
((t_mu111 - mean(m111'))/t_mu111)*100 mean(U_CP111') sum(count1)/nos...
mean(mu111') sqrt(mean(BM111)) ((t_mu111 - mean(mu111'))/t_mu111)*
100 mean(CP111') sum(count3)/nos;...
mean(m112') sqrt(mean(s112_1)/size2) ((t_mu112 - mean(m112'))/t_mu112)*
100 mean(U_CP112') sum(count1)/nos...
mean(mu112') sqrt(mean(BM112)) ((t_mu112 - mean(mu112'))/t_mu112)*
100 mean(CP112') sum(count3)/nos;...
mean(m121') sqrt(mean(s121_1)/size3) ((t_mu121 - mean(m121'))/t_mu121)*
100 mean(U_CP121') sum(count1)/nos...
mean(mu121') sqrt(mean(BM121)) ((t_mu121 - mean(mu121'))/t_mu121)*
100 mean(CP121') sum(count3)/nos;...
mean(m122') sqrt(mean(s122_1)/size4) ((t_mu222 - mean(m122'))/t_mu122)*
100 mean(U_CP122') sum(count1)/nos...
mean(mu122') sqrt(mean(BM122)) ((t_mu122 - mean(mu122'))/t_mu122)*
100 mean(CP122') sum(count3)/nos;...
mean(m211') sqrt(mean(s111_1_2a)/size1_2a)
((t_mu211 - mean(m211'))/t_mu211)*100 mean(U_CP211') sum(count1_2a)/nos...
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mean(mu211') sqrt(mean(BM211)) ((t_mu211 - mean(mu211'))/t_mu211)*
100 mean(CP211') sum(count3_2a)/nos;...
mean(m212') sqrt(mean(s112_1_2a)/size2_2a)
((t_mu212 - mean(m212'))/t_mu212)*100 mean(U_CP212') sum(count1_2a)/nos...
mean(mu212') sqrt(mean(BM212)) ((t_mu212 - mean(mu212'))/t_mu212)*
100 mean(CP212') sum(count3_2a)/nos;...
mean(m221') sqrt(mean(s121_1_2a)/size3_2a)
((t_mu221 - mean(m221'))/t_mu221)*100 mean(U_CP221') sum(count1_2a)/nos...
mean(mu221') sqrt(mean(BM221)) ((t_mu221 - mean(mu221'))/t_mu221)*
100 mean(CP221') sum(count3_2a)/nos;...
mean(m222') sqrt(mean(s122_1_2a)/size4_2a)
((t_mu222 - mean(m222'))/t_mu222)*100 mean(U_CP222') sum(count1_2a)/nos...
mean(mu222') sqrt(mean(BM222)) ((t_mu222 - mean(mu222'))/t_mu222)*
100 mean(CP222') sum(count3_2a)/nos];...
P2 =[mean(nmu111') sqrt(mean(B111)) ((t_mu111 - mean(nmu111'))/t_mu111)*100;
mean(nmu112') sqrt(mean(B112)) ((t_mu112 - mean(nmu112'))/t_mu112)*100;
mean(nmu121') sqrt(mean(B121)) ((t_mu121 - mean(nmu121'))/t_mu121)*100;
mean(nmu122') sqrt(mean(B122)) ((t_mu122 - mean(nmu122'))/t_mu122)*100;
mean(nmu211') sqrt(mean(B211)) ((t_mu211 - mean(nmu211'))/t_mu211)*100;
mean(nmu212') sqrt(mean(B212)) ((t_mu212 - mean(nmu212'))/t_mu212)*100;
mean(nmu221') sqrt(mean(B221)) ((t_mu221 - mean(nmu221'))/t_mu221)*100;
mean(nmu222') sqrt(mean(B222)) ((t_mu222 - mean(nmu222'))/t_mu222)*100];
%diary off
disp('pi0 & piR1 & piR2 & piB1 & piB2 & piC1 & piC2')
latex(PPi,'%.1f')
latex(PPower,'%.3f')
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disp('True & Estimates & SE & RelativeBias & CP & Power')
latex(P1,'%.2f')
sum(count_tot_1)/nos
sum(count_tot_3)/nos
% latex(P2,'%.2f')
%% True values are same under null no matter what response rates are
%% applied
A.2 NONPARAMETRIC INFERENCE ON MEDIAN RESIDUAL LIFE
FUNCTION IN SEQUENTIALLY RANDOMIZED TRIALS
clear all;
%same functions needed from previous code
%parameters
% ====================================================================
% Leukemia data set analysis
% ====================================================================
Pi_z = 0.5; % equally assigned to both maintenance treatments
t0 = 250; % time of interest
trtA = 1; %depend on induntion treatment option
% trtA = 2;
[id trt1 resp resp_time consent sec_rand_time trt2 death U age wbc]
= textread('C:\calgb1_.txt','%d %d %d %d %d %d %d %d %d %d %f ');
R = resp.*consent;
if trt2 == 2
trt2 = 0;
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end
Z = trt2;
D = death; % 0 for censored
n = length(D);
for i=1:n
if (Z(i)==2)
Z(i) = 0;
else Z(i) = Z(i);
end
if D(i)==0
D1(i)=1;
else D1(i)=0;
end
end
D1=D1';
% for first or second treatment option in induction treatment
index_vector = find(trt1==trtA);
R = R(index_vector);
Z = Z(index_vector);
D = D(index_vector);
D1 = D1(index_vector);
U = U(index_vector);
resp_time = resp_time(index_vector);
n = length(D);
% Kaplan-Meier Estimators
[K,x] = ecdf(U,'censoring',D,'function','survivor');
[S,x1] = ecdf(U,'censoring',D1,'function','survivor');
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K = fOne(U,x,K);
S = fOne(U,x1,S);
for j = 1:n
if K(j) == 0 K(j) = K(j-1); end
if S(j) == 0 S(j) = S(j-1); end
end
% weight functions
Q2=1-R + ((R.*(1-Z))/(1- Pi_z));
Q1=1-R + ((R.*Z)/Pi_z);
Cens = D./K';
K = K';
save FileforSecant D K Q1 Q2 U t0 n;
%Secant method to find Theta
[Theta31,fncvalue,err,hist] = secant1('secfunc1',0,500,1.0e-16,
1.0e-16,10000);
[Theta32,fncvalue,err,hist] = secant1('secfunc2',0,500,1.0e-16,
1.0e-16,10000);
K = K';
% Survival for each time point;
for j = 1:n
S01 = Cens.*Q1.*(U>U(j));
S02 = Cens.*Q2.*(U>U(j));
S1(j) = sum(S01)/sum(Cens.*Q1);
S2(j) = sum(S02)/sum(Cens.*Q2);
end
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S1_t0 = fOne(t0,U,S1);
S2_t0 = fOne(t0,U,S2);
S_half1 = 0.5*S1;
S_half2 = 0.5*S2;
S_half1_t0 = fOne(t0,U,S_half1);
S_half2_t0 = fOne(t0,U,S_half2);
%Find S inverse for 0.5*S(t)
Sinv1 = fOne(S_half1, S1, U);
Sinv2 = fOne(S_half2, S2, U);
Sinv1_t0 = fOne(t0,U,Sinv1);
Sinv2_t0 = fOne(t0,U,Sinv2);
%kernel density to find density of S
[den1,xi1] = ksdensity(U,'weights',Q1,'censoring',D1,
'npoints',n);
[den2,xi2] = ksdensity(U,'weights',Q2,'censoring',D1,
'npoints',n);
Den21 = fOne(U,xi1,den1);
Den22 = fOne(U,xi2,den2);
Den21_t0 = fOne(t0,U,Den21);
Den22_t0 = fOne(t0,U,Den22);
% MERL Theta 1
for j = 1:n
Theta11(j) = Sinv1(j) - U(j);
Theta12(j) = Sinv2(j) - U(j);
end
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Theta11_t0 = fOne(t0,U,Theta11);
Theta12_t0 = fOne(t0,U,Theta12);
% density for theta 1 +t0 and theta3+t0
Den31_the = fOne(Theta31+t0,U,Den21);
Den32_the = fOne(Theta32+t0,U,Den22);
Den11_the_new = fOne(Theta11_t0+t0, U,Den21);
Den12_the_new = fOne(Theta12_t0+t0, U,Den22);
U_new1 = U' + Theta11;
U_new2 = U' + Theta12;
[den1_new,xi1_new] = ksdensity(U_new1,'npoints',n,
'weights',Q1);
[den2_new,xi2_new] = ksdensity(U_new2,'npoints',n,
'weights',Q2);
Den11_the = fOne(U_new1,xi1_new,den1_new);
Den12_the = fOne(U_new2,xi2_new,den2_new);
% /* Y(u) and Y(u)^-1
for j = 1:n
Y(j) = sum(U >= U(j));
Y_inv(j) = (sum(U >= U(j))).^-1;
end
%Aalan-Nelson Est.
for j = 1:n
if (U(j) < t0) & (D(j) ==1)
68
ANe(j) = sum(Y_inv(j));
end
end
%finding variances
for j = 1:n
for k = 1:n
G11(j,k) = sum(Cens.*Q1.*((U>U_new1(j))- 0.5.*(U>U(j)))
.*(U>=U(k)))./(n.*S(k));
G12(j,k) = sum(Cens.*Q2.*((U>U_new1(j))- 0.5.*(U>U(j)))
.*(U>=U(k)))./(n.*S(k));
E11(j,k) = sum(Cens.*(Q1.*((U>U_new1(j))- 0.5.*(U>U(j)))
-G11(j,k)).^2.*(U >= U(k)))/n;
E12(j,k) = sum(Cens.*(Q2.*((U>U_new1(j))- 0.5.*(U>U(j)))
-G12(j,k)).^2.*(U >= U(k)))/n;
G21(j,k) = sum(Cens.*Q1.*(U>U(j)).*(U>=U(k)))./(n.*S(k));
G22(j,k) = sum(Cens.*Q2.*(U>U(j)).*(U>=U(k)))./(n.*S(k));
E21(j,k) = sum(Cens.*(Q1.*(U>U(j))-G21(j,k)).^2.*
(U >= U(k)))/n;
E22(j,k) = sum(Cens.*(Q2.*(U>U(j))-G22(j,k)).^2.*
(U >= U(k)))/n;
end
end
for j = 1:n
V_second11(j) = sum((1-D)'.*E11(j,:)./(K.*Y));
V_second12(j) = sum((1-D)'.*E12(j,:)./(K.*Y));
V_second21(j) = sum((1-D)'.*E21(j,:)./(K.*Y));
V_second22(j) = sum((1-D)'.*E22(j,:)./(K.*Y));
V_first11(j) = sum(Cens.*((Q1.*((U>U_new1(j))- 0.5
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.*(U>U(j)))).^2))/n;
V_first12(j) = sum(Cens.*((Q2.*((U>U_new1(j))- 0.5
.*(U>U(j)))).^2))/n;
V_first21(j) = sum(Cens.*((Q1.*(U>U(j))-S1(j)).^2))/n;
V_first22(j) = sum(Cens.*((Q2.*(U>U(j))-S2(j)).^2))/n;
var11(j) = (V_first11(j) + V_second11(j))/n;
var12(j) = (V_first12(j) + V_second12(j))/n;
var21(j) = (V_first21(j) + V_second21(j))/n;
var22(j) = (V_first22(j) + V_second22(j))/n;
Var11(j) = var11(j)/(Den11_the(j)^2);
Var12(j) = var12(j)/(Den12_the(j)^2);
Var21(j) = var21(j)/(4*(Den21(j)^2));
Var22(j) = var22(j)/(4*(Den22(j)^2));
Se11(j) = sqrt(Var11(j));
Se12(j) = sqrt(Var12(j));
Se21(j) = sqrt(Var21(j));
Se22(j) = sqrt(Var22(j));
CL_L11(j) = Theta11(j) -1.96* Se11(j);
CL_U11(j) = Theta11(j) + 1.96*Se11(j);
CL_L12(j) = Theta12(j) -1.96* Se12(j);
CL_U12(j) = Theta12(j) + 1.96*Se12(j);
CL_L21(j) = Theta11(j) -1.96* Se21(j);
CL_U21(j) = Theta11(j) + 1.96*Se21(j);
CL_L22(j) = Theta12(j) -1.96* Se22(j);
CL_U22(j) = Theta12(j) + 1.96*Se22(j);
end
Se11_t0 = fOne(t0,U,Se11);
Se12_t0 = fOne(t0,U,Se12);
Se21_t0 = fOne(t0,U,Se21);
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Se22_t0 = fOne(t0,U,Se22);
CL_L11_t0 = fOne(t0,U,CL_L11);
CL_U11_t0 = fOne(t0,U,CL_U11);
CL_L12_t0 = fOne(t0,U,CL_L12);
CL_U12_t0 = fOne(t0,U,CL_U12);
% sandwich estimator for theta 1
AA1 = Den11_the_new.^2;
AA2 = Den12_the_new.^2;
BB1 = sum(((Cens.*Q1.*((U>t0+Theta11_t0)-0.5.*(U>t0)))).^2)/
(sum(Cens.*Q1));
BB2 = sum(((Cens.*Q2.*((U>t0+Theta12_t0)-0.5.*(U>t0)))).^2)/
(sum(Cens.*Q2));
Var31 = (BB1/AA1)/n;
Var32 = (BB2/AA2)/n;
Se31 = sqrt(Var31);
Se32 = sqrt(Var32);
% sandwich estimator for theta 3 from secant
AA31 = Den31_the.^2;
AA32 = Den32_the.^2;
BB31 = sum(((Cens.*Q1.*((U>t0+Theta31)-0.5.*(U>t0)))).^2)/
(sum(Cens.*Q1));
BB32 = sum(((Cens.*Q2.*((U>t0+Theta32)-0.5.*(U>t0)))).^2)/
(sum(Cens.*Q2));
Var331 = (BB31/AA31)/n;
Var332 = (BB32/AA32)/n;
Se331 = sqrt(Var331);
Se332 = sqrt(Var332);
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K = K';
psi11 = (D./K).*Q1.*(U>t0).*R.*(resp_time<=t0).*Z;
psi12 = (D./K).*Q1.*(U>t0).*(1-R).*(resp_time<=t0).*Z;
psi31 = (D./K).*Q2.*(U>t0).*R.*(resp_time<=t0).*Z;
psi32 = (D./K).*Q2.*(U>t0).*(1-R).*(resp_time<=t0).*Z;
psi21 = (D./K).*R.*(resp_time<=t0);
psi22 = (D./K).*(1-R).*(resp_time<=t0);
%======================================================================
% Variance by M-estimation
%======================================================================
A1 = [Den11_the_new 0; 0 -1];
B1 = [sum(psi11.^2)/n sum(psi11.*psi21)/n; sum(psi11.*psi21)/n
sum(psi21.^2)/n];
invA1 = inv(A1);
V1 = (invA1*B1*invA1')./n;
A2 = [Den12_the_new 0; 0 -1];
B2 = [mean(psi11.^2) mean(psi12.*psi22); mean(psi12.*psi22)
mean(psi22.^2)];
invA2 = inv(A2);
V2 = (invA2*B2*invA2')./n;
new_var = V1+V2;
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out = [Theta11_t0 Se11_t0 Se31 Theta31 Se331 Theta41_t0 Se41];
out1= [Theta12_t0 Se12_t0 Se32 Theta32 Se332 Theta42_t0 Se42];
latex(out,'%.2f')
latex(out1,'%.2f')
% ======================================================================
% Simulation study for Median Residual Life Function
% ======================================================================
A = 3.5;
Pi_r = 0.4;
Pi_z = 0.5;
t0 = 365;
nu = 2;
rho = 0.2;
%1000 iterations and sample size
nos = 1000;
n = 200;
%% values for different scenrios
% mu31 = 267; mu32 = 235; %183, 0.4, 0.5
mu31=234.3; mu32=193.4; %365, 0.4, 0.5
% % mu31 = 341.9; mu32 = 285.6; %183 0705
% mu31 = 262.9; mu32 = 209.5; %365 0705
% mu31 = 273.9; mu32 = 239.9; %183 0403
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% mu31 = 234.3; mu32 = 193.4; %365 0403
% mu31 = 343.5; mu32 = 285.1; %183 0703
% mu31 = 262.1; mu32 = 210.4; %365 0703
for l = 1:nos
%C for Censroing~Uni(0,A);
c = rand(n,1);
C = A*c;
ind1 = 0;
ind2 = 0;
index2 = 0;
index3 = 0;
index4 = 0;
r = rand(n,1);
z = rand(n,1);
% **Generating R from b(1,Pi_r) for Consent indicator;
R = zeros(n,1);
Z = zeros(n,1);
Tnr = zeros(n,1);
Ta = zeros(n,1);
T1 = zeros(n,1);
T2 = zeros(n,1);
for i = 1:n
% indicator for receiving second treatment
if r(i) < Pi_r
R(i,1) = 1;
else
R(i,1) = 0;
end
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end
for i = 1:n
if R(i) == 1
% Generating Z from bin(1, Pi_z) for trt B1 indicator;
if z(i) < Pi_z
Z(i,1) = 1;
else
Z(i,1) = 0;
end
else
Z(i,1) = -1;
end
end
ind1 = find(R==0);
ind2 = find(R==1);
Tnr(ind1) = expinv(rand(length(ind1),1),0.5);
% failure times are exponential(exp(beta1))under R=0
Ta(ind2) = expinv(rand(length(ind2),1),0.1);
% failure times are exponential(exp(beta1))under R=1
u11 = rand(length(ind2),1);
u12 = rand(length(ind2),1);
T1(ind2) = ((1/rho).*(-exp(-0.6).*log(1-u11))).^(1/nu);
T2(ind2) = ((1/rho).*(-exp(-0.9).*log(1-u12))).^(1/nu);
T = ((R.*((Z).*(Ta + T1) + (1-Z).*(Ta + T2)) + (1-R).*Tnr));
Tr = R.*Ta + (1-R).*Tnr;
U = min(T,C);
D = (T <= C); % 1 for not censoring
data = [U R Z D Tr Ta Tnr];
data = sortrows(data);
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U = data(:,1);
R = data(:,2);
Z = data(:,3);
D = data(:,4);
Tr = data(:,5);
Ta = data(:,6);
Tnr = data(:,7);
D(n,1) = 1;
D1 = 1-D;
U=U*365.25;
Tr = Tr*365.25;
Ta = Ta*365.35;
Tnr = Tnr*365.25;
% weight
Q1 = (1-R) + ((R.*Z)./Pi_z);
Q2 = (1-R) + ((R.*(1-Z))./(1-Pi_z));
%KMe
[K,sk] = kmest(U,D);
[S,ss] = kmest(U,D1);
% save files for EEB method
save FileforSecant D K Q1 Q2 U t0 n;
%======================================================================
% SSB method & Taylor
%======================================================================
% SampleSize adjusted survival estimates for each time point;
S1 = 0; S2 = 0;
for j = 1:n
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S1(j) = 1-sum(D./K.*Q1.*(U<=U(j)))/sum(D./K.*Q1);
S2(j) = 1-sum(D./K.*Q2.*(U<=U(j)))/sum(D./K.*Q2);
end
% S1 = S_1(:,l);
% S2 = S_2(:,l);
S1_t0 = fOne(t0,U,S1);
S2_t0 = fOne(t0,U,S2);
[S_half1 Sinv1 Sinv1_t0(l) S_half1_t0] = S_find(S1, U, t0);
[S_half2 Sinv2 Sinv2_t0(l) S_half2_t0] = S_find(S2, U, t0);
[Den21 Den21_t0] = denS(U, Q1, D1, t0);
[Den22 Den22_t0] = denS(U, Q2, D1, t0);
% **MERL Theta 1 and 2**;
Theta11_t0(l) = Sinv1_t0(l) - t0;
Theta12_t0(l) = Sinv2_t0(l) - t0;
Theta21_t0(l) = S_half1_t0/Den21_t0;
Theta22_t0(l) = S_half2_t0/Den22_t0;
% density for theta1+t0
Den11_the_new = fOne(Theta11_t0(l)+t0, U,Den21);
Den12_the_new = fOne(Theta12_t0(l)+t0, U,Den22);
%theta plus t0
U_new1_t0 = t0 + Theta11_t0(l);
U_new2_t0 = t0 + Theta12_t0(l);
% Y(u) and Y(u)^-1
Y = 0; Y_inv = 0;
for j = 1:n
Y(j) = sum(U >= U(j));
Y_inv(j) = (sum(U >= U(j))).^-1;
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end
% Var and CP by Lunceford
[Se11(l) Cp11(l)] = CP5(D, K, Q1, U, U_new1_t0, t0, S, Y,
Theta11_t0(l), mu31, Den11_the_new);
[Se12(l) Cp12(l)] = CP5(D, K, Q2, U, U_new2_t0, t0, S, Y,
Theta12_t0(l), mu32, Den12_the_new);
[Se21(l) Cp21(l)] = CP6(D, K, Q1, U, t0, S, Y, Theta11_t0(l),
mu31, Den21_t0, S1_t0);
[Se22(l) Cp22(l)] = CP6(D, K, Q2, U, t0, S, Y, Theta12_t0(l),
mu32, Den22_t0, S2_t0);
% Var and CP by Sandwich for theta 1
[Var31 Var32 Se31(l) Se32(l) Cp31(l) Cp32(l)] =
CP1(Den11_the_new, Den12_the_new, D, K, Q1, Q2, U, t0,
Theta11_t0(l), Theta12_t0(l), mu31, mu32);
%======================================================================
% EEB method
%======================================================================
% estimates for MERL times by EEB
[Theta31(l),fncvalue31(l),err,hist] =
secant1('secfunc1',0,400,1.0e-16,1.0e-16,10000);
[Theta32(l),fncvalue32(l),err,hist] =
secant1('secfunc2',0,400,1.0e-16,1.0e-16,10000);
% Density for theta3 + t0
Den31_t0 = fOne(Theta31(l)+t0,U,Den21);
Den32_t0 = fOne(Theta32(l)+t0,U,Den22);
% Var and CP for theta 3 from secant by sandwich
[Var331 Var332 Se331(l) Se332(l) Cp331(l) Cp332(l)] = ...
CP1(Den31_t0, Den32_t0, D, K, Q1, Q2, U, t0,
Theta31(l), Theta32(l), mu31, mu32);
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end
Out = [mean(Theta11_t0) mean(Se11) sqrt(var(Theta11_t0)) mean(Cp11) ;
mean(Theta12_t0) mean(Se12) sqrt(var(Theta12_t0)) mean(Cp12);
mean(Theta11_t0) mean(Se31) sqrt(var(Theta11_t0)) mean(Cp31) ;
mean(Theta12_t0) mean(Se32) sqrt(var(Theta12_t0)) mean(Cp32) ;
mean(Theta21_t0) mean(Se21) sqrt(var(Theta21_t0)) mean(Cp21) ;
mean(Theta22_t0) mean(Se22) sqrt(var(Theta22_t0)) mean(Cp22) ;
mean(Theta31) mean(Se331) sqrt(var(Theta31)) mean(Cp331) ;
mean(Theta32) mean(Se332) sqrt(var(Theta32)) mean(Cp332);
mean(Theta41_t0) mean(Se41) sqrt(var(Theta41_t0)) mean(Cp41);
mean(Theta42_t0) mean(Se42) sqrt(var(Theta42_t0)) mean(Cp42)];
out = latex(Out,'%.2f')
[mean(Se51) mean(Se52)]
% save MERL_0812_R0705_N200_T183.mat
%Relative bias
RB11 = ((mu31 - mean(Theta11_t0))/mu31)*100;
RB12 = ((mu32 - mean(Theta12_t0))/mu32)*100;
RB31 = ((mu31 - mean(Theta31))/mu31)*100;
RB32 = ((mu32 - mean(Theta32))/mu32)*100;
RB41 = ((mu31 - mean(Theta41_t0))/mu31)*100;
RB42 = ((mu32 - mean(Theta42_t0))/mu32)*100;
Out1 = [RB11 RB12 RB31 RB32 RB41 RB42];
out1 = latex(Out1,'%.1f')
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